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Abstract 
Association Between Serum 25-Hydroxyvitamin D Concentration And Type 2 
Diabetes Mellitus: Interaction By Race/Ethnicity And Mediation By Inflammation 
Shaum Mohan Kabadi 
 
 
 
 Diabetes mellitus affects 25.6 million adults and is the seventh leading 
cause of death in the United States. Recent evidence indicates that vitamin D 
may alter glucose metabolism, which suggests it may play a role in reducing risk 
of prediabetes and type 2 diabetes. Although observational studies support 
pancreatic β-cell dysfunction and insulin resistance as pathways by which vitamin 
D influences glucose homeostasis, a mechanism involving systemic inflammation 
remains obscure. We hypothesized that vitamin D was associated with 
inflammation, prediabetes, and type 2 diabetes. In the present investigation, we 
analyzed data from the National Health and Nutrition Examination Survey 
(NHANES) conducted from 2001-2006 among adults over 20 years of age. We 
evaluated the association between 25-hydroxyvitamin D [25(OH)D], a serum 
biomarker of vitamin D status, and prediabetes or type 2 diabetes. In addition, we 
assessed the association by subgroups of gender and race/ethnicity and 
evaluated interaction using joint effects. We determined the association between 
25(OH)D and three biomarkers of inflammation, including C-reactive protein 
(CRP), and further assessed mediation by CRP on the association between 
25(OH)D and hemoglobin A1c [HbA1c], a biomarker of glucose homeostasis.  
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 Using piecewise regression, it was determined that 25(OH)D was 
inversely associated with CRP when 25(OH)D < 20 ng/mL, but directly 
associated when 25(OH)D ≥ 20 ng/mL. There was significant interaction by age, 
gender, race/ethnicity, and abdominal obesity. Furthermore, 25(OH)D was not 
associated with fibrinogen but inversely associated with homocysteine. Results 
from path analysis indicate that CRP mediated 14.9% of the association between 
25(OH)D and HbA1c in males. We determined that 25(OH)D sufficiency was 
associated with type 2 diabetes. However, the association was not significant in 
non-Hispanic Blacks which suggests that 25(OH)D sufficiency as defined by the 
Institute of Medicine may be inadequate for this subgroup. Our finding that 
vitamin D may prevent diabetes is consistent with prospective studies which 
supports a temporal association. Although these findings need to be confirmed in 
prospective studies and intervention trials, our results may be of large public 
health value in controlling the current unfavorable diabetes epidemic.   
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1. BACKGROUND AND LITERATURE REVIEW 
 
 
Recent evidence suggests that vitamin D status, assessed by serum 25-
hydroxyvitamin D [25(OH)D], may play a role in development of type 2 diabetes. 
However, current data is insufficient to support the hypothesis that serum 
25(OH)D concentration is inversely associated with risk of type 2 diabetes.1-8  
1.1.  Diabetes mellitus epidemiology, etiology, and established risk factors  
 
1.1.1. Epidemiology and Statistics 
 Diabetes mellitus is recognized as one of the leading causes of death and 
disability in the United States. Diabetes was the seventh leading cause of death 
listed on U.S. death certificates in 2010.9 Diabetes was listed as a contributing 
factor on an additional 160,022 death certificates meaning that diabetes 
contributed to a total of 231,404 deaths.10 According to the 2011 National 
Diabetes Fact Sheet, 11.3% of people in the United States aged 20+ have 
diabetes mellitus; this estimate represents 25.6 million individuals. About 90 to 95 
percent of people with diabetes have type 2 diabetes mellitus.10 
 Diabetes is associated with long-term complications that can potentially 
impact almost every part of the body. Diabetes can lead to blindness, heart and 
blood vessel disease, stroke, kidney failure, amputations, and nerve damage. 
The total costs of diagnosed diabetes in the United States in 2007 were $174 
billion.10 Indirect costs, including disability payments, time lost from work, and 
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reduced productivity summed to $58 billion.10 Direct medical costs for diabetes 
care, including hospitalizations, medical care, and treatment supplies totaled 
$116 billion.10 
 There are an estimated 79 million people living in the United States who 
have prediabetes10 meaning that they are at high risk for diabetes. Before type 2 
diabetes, individuals almost always pass through prediabetes—blood glucose 
concentration that are higher than normal but not yet high enough to be 
diagnosed as diabetes.10  
1.1.2. Etiology 
 Diabetes mellitus refers to a group of metabolic diseases that affect how the 
body uses blood glucose. Food that people eat is broken down into glucose, 
which is the main source of fuel for the body. After food is digested by the 
stomach and small intestine, glucose passes into the bloodstream, where it is 
used by cells for maintenance and growth. Glucose cannot get into cells without 
insulin. Insulin is a hormone produced by the pancreas. After food is digested, 
the pancreas automatically produces the right amount of insulin to move glucose 
from the blood into the cells. In people with diabetes, however, the pancreas 
either produces little or no insulin (type 1 diabetes), or the cells do not respond 
appropriately to the insulin that is produced (type 2 diabetes). Subsequently, 
glucose builds up in the blood and passes out of the body through urine. 
Therefore, the body is unable to utilize its main energy source even when there is 
enough glucose in the blood.  
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 The two main forms of diabetes are type 1 and type 2 diabetes mellitus. Type 
1 diabetes is an autoimmune disease where the body’s system for fighting 
infection—the immune system—destroys the insulin-producing β-cells in the 
pancreas. Therefore, the pancreas produces little or no insulin. In type 2 
diabetes, the pancreas is typically producing enough insulin, but cannot use 
efficiently utilize insulin, which is known as insulin resistance. After many years of 
having type 2 diabetes, insulin production decreases. At that point, glucose 
builds up in the blood but the body cannot make appropriate use of it.  
 
1.1.3. Established risk factors for type 2 diabetes 
 
1.1.3.1. Age, race/ethnicity, gender, and family history 
 Diabetes is more prevalent in the elderly compared to younger individuals. 
NHANES III indicates that the prevalence of physician-diagnosed diabetes and 
undiagnosed diabetes is significantly greater as participants become older.11 In 
addition, more recent data from NHANES 2005-2008 indicates the prevalence of 
diabetes is 27% among those over the age of 65, 14% among those aged 45-64, 
and 4% among those aged 20-44.10 Potential mechanisms include decreased 
efficiency of the pancreas to produce insulin or cells becoming more resistant to 
insulin.  An animal study found that overexpression of the human catalase gene 
helped to improve mitochondrial function and insulin sensitivity in aging mice.12 
These study results suggest that increased diabetes risk among aging individuals 
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is may be attributed to decreased mitochondrial function. The association of age 
with weight is also a plausible reason for increased risk of diabetes since obesity 
is associated with insulin resistance.13-16  
 Data from the National Health Interview Survey 2007-2009 indicates that 
racial disparities exist in diabetes prevalence.10 Among adults over the age of 20, 
the prevalence of diabetes was higher for non-Hispanic Blacks and Hispanics 
than non-Hispanic Whites and Asian Americans. High blood pressure17 and 
obesity18 might help to explain this disparity. 
 The prevalence of diabetes among those over the age of 20 is higher in men 
than in women.10 The reason for this is likely explained by differences in blood 
pressure and waist circumference. Attempts to elucidate differences in gender 
risk have been mostly unsuccessful. In the Diabetes Prevention Program where 
participants without diabetes were randomized to receive placebo, metformin, or 
forced lifestyle-modification, it was found that men were more physically active 
and lost more weight at the end of 3 years but experienced the same reduction in 
incidence of diabetes as women.19 In an attempt to determine if sex differences 
exist in risk factors for diabetes, a different analysis of the Diabetes Prevention 
Program was conducted.20 It was concluded that because of the higher number 
risk factors present in males at baseline compared to women, any differences in 
incident diabetes due to gender were obscured.  
 Evidence from the NHANES 1999-2004 indicates that among 16,388 adults 
in the U.S. population, family history was a significant and independent predictor 
of diabetes prevalence.21 Participants with a high familial risk of diabetes had a 
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5.5 times increased risk of diabetes compared to those with an average familial 
risk of diabetes. Higher familial risk of diabetes indicates closer blood relation to 
the individual while average familial risk of diabetes indicates either no family 
history of diabetes or, at most, one second-degree relative with diabetes. 
Prospective studies have also indicated that family history of diabetes is a risk 
factor for diabetes. 22,23 Results from the Framingham Offspring Study indicate 
that parental diabetes was an independent risk factor for diabetes after 7 years of 
follow-up. 22 This increased risk is probably due to a combination of genetic risk 
variants24-26 and shared lifestyle factors.27 
 
1.1.3.2. Obesity, physical activity, and diet 
 Obesity is a strong risk factor for type 2 diabetes. A meta-analysis found that 
among relatively large (greater than 400 cases of incident type 2 diabetes) 
prospective studies, after adjustment for the main confounding variables, obesity 
was associated with a 7.28-fold [95% CI: 6.47, 8.28] increased risk of type 2 
diabetes compared to normal weight persons.28 
 Obesity and diabetes are both linked with insulin resistance. 29 Insulin 
resistance is a condition in which a given concentration of insulin produces a 
weaker biological effect than expected. 30 Insulin is a hormone critical in 
regulating glucose metabolism in the body. It causes cells in the liver, muscle, 
and fat tissue to take up glucose from the blood.  The imbalance in glucose 
metabolism caused by insulin resistance is what leads to diabetes onset.  
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 The most critical factor in the emergence of metabolic diseases is obesity. 
Adipose tissue modulates metabolism by releasing non-esterified fatty acids and 
glycerol, hormones — including leptin and adiponectin — and proinflammatory 
cytokines.31-33 When insulin resistance is joined by dysfunctional pancreatic islet 
β-cells — the cells that release insulin —failure to control blood glucose 
concentration results. 13  
 The distribution of body fat can also impact risk of diabetes. Fat that is 
centralized around the waist is associated with a high risk of diabetes. Since 
precisely measuring abdominal fat content requires expensive radiological 
imaging techniques, waist circumference is often used as a surrogate marker of 
abdominal fat mass, because waist circumference correlates with abdominal fat 
mass and is associated with diabetes risk.34 Furthermore, abdominal obesity, 
defined as WC ≥102 cm for men and WC≥88 cm for women,35 may be a better 
predictor of diabetes risk than general obesity indicated by BMI.36,37 
 Physical activity can help to maintain a normal body weight but also may 
help the body’s cells use insulin more efficiently38-40, which can reduce the risk of 
diabetes. 41,42 Moreover, physical activity can also help to improve lipid 
concentration, lower blood pressure, and improve blood glucose management.41-
43 In a meta-analysis of 10 prospective cohort studies, regular participation in 
physical activity of moderate intensity resulted in a 31% (RR=0.69, 95% CI: 0.58-
0.83) reduced risk of diabetes compared with being sedentary.  In a post-hoc 
analysis of the Finnish Diabetes Prevention Study, increased leisure-time 
7 
 
 
physical activity during a 4.1 year follow-up period was associated with a 
decreased risk of diabetes independent of changes in diet and body weight.44  
 Although high caloric intake is associated with obesity which can impact risk 
of diabetes, diet quality is also an important component. Diet quality has long 
been known to influence blood glucose concentration and risk of diabetes.45 For 
example, results from a nutrition-interventional trial indicate that a Mediterranean 
diet is associated with a 52% lower risk of diabetes after adjustment for total 
caloric intake.46 Briefly, a Mediterranean diet includes abundant use of olive oil in 
food preparation; increased consumption of fruits, vegetables, legumes, and fish; 
reduction in total meat consumption; and, avoidance of butter, cream, fast-food, 
sweets, pastries, and sugar-sweetened beverages.  
 In addition, analysis of data from the Nurses’ Health Study found that high 
glycemic load and trans fat was associated with an increased risk of diabetes; 
furthermore, cereal fiber and polyunsaturated fat was associated with a lower risk 
of diabetes.47 Women free of diagnosed cardiovascular disease, diabetes, and 
cancer were followed for 16 years. The results of this publication provided insight 
into diet composition and impact on diabetes risk. In a separate analysis of data 
from the Nurses’ Health Study, higher intake of whole-grain was associated with 
lower risk of diabetes.48 Furthermore, there was a stronger protective effect with 
intake of bran whole grain than germ intake; the overall results suggest that 
increasing whole grain consumption can prevent diabetes. Evidence strongly 
supports the hypothesis that consumption of sugar-sweetened beverages is an 
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independent risk factor for incident diabetes.49  A meta-analysis found that 
persons in the highest quantile of sugar-sweetened beverage consumption 
compared to the lowest quantile had a 26% increased risk of diabetes (RR=1.26, 
95% CI: 1.12-1.41). Increased blood glucose concentration due to consumption 
of sugar-sweetened beverages can weaken pancreatic β-cells which may explain 
the increased diabetes risk.   
1.1.3.3. High blood pressure 
 Analysis of data from the Strong Heart Study indicates that high blood 
pressure is an independent risk factor for incident diabetes. 50 Although a precise 
biological mechanism has not been identified, elevated blood pressure may 
cause insulin resistance which can explain the increased risk of diabetes. These 
results were also consistent with previous manuscripts in the scientific literature. 
51,52 Furthermore, this association has been generally been consistent in different 
gender, age, and racial/ethnic groups. 53-57  
1.1.3.4. Abnormal lipid metabolism 
 Low high-density lipoprotein (HDL) cholesterol and high triglycerides are 
associated with diabetes incidence.58-60 In a prospective study with a 15-year 
follow up period, triglycerides (OR=1.29, p=0.05) and triglycerides/HDL (1.34, 
p=0.01) independently predicted type 2 diabetes.59 A proposed mechanism 
suggests high lipid concentration can damage β-cells which can cause 
diabetes.61 The author suggests that lowering lipid concentration helps to lower 
blood sugar, which is consistent with the lipocentric perspective of type 2 
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diabetes. The glucocentric perspective views high blood sugar as the primary 
outcome but the lipocentric view depicts high blood sugar as being secondary to 
the high lipid concentration. Therefore, it can be argued that high blood sugar 
can be corrected for by decreasing lipid concentration.  
1.1.3.5  Smoking 
Smoking can increase risk of diabetes by increasing blood sugar and 
exacerbating insulin sensitivity.62-65 The most recently published study on this 
topic was an analysis of data from the Atherosclerosis Risk in Communities 
Study.65 Among a large sample of middle-age adults, the heaviest smokers had a 
higher risk of incident type 2 diabetes (HR=1.42, 95% CI: 1.20-1.67) compared to 
non-smokers. After quitting smoking, the greatest risk of diabetes occurred within 
the first 3 years (HR=1.91, 95% CI: 1.19 to 3.05) and decreased to null after 12 
years. 
 
1.2 Vitamin D 
1.2.1. Metabolism of vitamin D 
 Vitamin D plays an important role in the endocrine system because 1,25-
dihydroxyvitamin D [1,25(OH)2D], the active form of vitamin D, is responsible for 
the maintenance of serum calcium and phosphate concentration. Vitamin D is 
part of a group of fat-soluble seco-sterols and can be obtained from sunlight, 
food or supplements.67 The two major forms are vitamin D2 (largely human-made 
and added to foods) and vitamin D3 (produced though skin of humans or 
10 
 
 
consumed though intake of animal-based foods).2 The D2 (ergocalciferol) and D3 
(cholecalciferol) forms differ only in their side chain structure; they are 
metabolized similarly and both forms function as prohormones (precursor to 
hormone which on its own has minimal impact). When activated, the D2 and D3 
forms have been reported to exhibit identical responses in the body.  
 Whether obtained through sunlight or diet, vitamin D is biologically inactive 
and must be activated through hydroxylation. Vitamin D is first hydroxylated in 
the liver where it is converted by the 25-hydroxylase enzyme to 25(OH)D, the 
main form of circulating vitamin D, also known as calcidiol. Subsequently 
25(OH)D is hydroxylated by the 1-α-hydroxylase enzyme in the kidney where it 
forms the biologically active 1,25(OH)2D, also known as calcitriol.2  
 
1.2.2  Function of vitamin D 
 The primary function of vitamin D is to maintain adequate serum 
concentration of calcium and phosphorus. In the absence of vitamin D, 
approximately 10% of calcium and 60% of phosphorus is absorbed.68,69 In the 
presence of intestinal vitamin D receptors, 1,25(OH)2D improves calcium 
absorption to 40% and phosphorus absorption to 80%. 68-70 Moreover, vitamin D 
is needed by osteoblasts and osteoclasts to allow for optimal bone health. 2,71 In 
an analysis of NHANES III data among 13,432 participants, higher serum 
25(OH)D concentration was associated with higher bone mineral density in all 
age and racial/ethnic groups.72 Adequate serum concentration of 25(OH)D and 
bone mineral density predict lower incidence of fractures and osteoporosis.2 
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 Low serum 25(OH)D concentration is associated with poor muscle function. 
73-75 The presence of vitamin D receptors on skeletal muscles supports this 
statement.69 Evidence indicates that performance speed and muscle strength 
were enhanced as 25(OH)D concentration increased from 4 to 16 ng/mL. 75 The 
presence of vitamin D receptors on immune cells2,68  allows for 1,25(OH)2D to 
serve as an immunomodulator.68,76 1,25(OH)2D stimulates insulin secretion in the 
β-cells of the pancreas.77 Furthermore, 25(OH)D concentration is associated with 
insulin resistance and systemic inflammation.1 
 
1.2.3. Sources of vitamin D 
 There are several factors known to influence circulating 25(OH)D 
concentration, including UV-B radiation intensity, sun exposure, skin 
pigmentation, diet/supplemental vitamin D intake, and weight.78 Observational 
studies have consistently shown that vitamin D from sunlight and dietary intake 
contribute towards serum 25(OH)D concentration.79-81 
 
1.2.2.1. Sunlight 
 Vitamin D is synthesized in the skin by solar ultraviolet (UV) B radiation 
(wavelength of 290–320 nanometers) which converts cutaneous 7-
dehydrocholesterol to previtamin D3, which in turn becomes vitamin D3,2 which is 
released in the bloodstream slowly while bound to an α-globulin.82 Most people 
meet at least some of their vitamin D needs through exposure to sunlight.81,83-85 
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Sunlight likely contributes more to serum 25(OH)D concentration than diet 
overall.86 In British Caucasians, sunlight contributed 70-85% to 25(OH)D87 
although it has been found to be as low as 38% in Italian Caucasian workers.83 
 Season, time of day, length of day, cloud cover, smog, skin melanin content, 
and sunscreen are among the factors that affect UV radiation exposure and 
vitamin D synthesis.2 Substantial seasonal variation in 25(OH)D concentration 
exists, especially in elderly populations, with serum 25 OHD concentration 
reaching a low during the winter and high during the summer;83,84,88-90 this is very 
likely to be related to the seasonal changes in UV sunlight exposure.   
 Being exposed to enough UV-B radiation to cause a slight pinkness to the 
skin in light-skinned persons typically produces a vitamin D response equivalent 
to 20,000 IU of vitamin D.91 A darker skinned individual may require an exposure 
to UV-B radiation of more than 10 times that of a light-skinned person to produce 
the equivalent amount of vitamin D.92 There is evidence of 25(OH)D deficiency 
even in sunlight rich areas in populations with dark skin.93-98 The degree of skin 
pigmentation plays a large role in vitamin D status because melanin filters out 
UV-B radiation. 
 Obesity or high BMI has typically been linked with lower blood concentrations 
of 25(OH)D.99  Because vitamin D is fat soluble, it is likely that obese individuals 
do not have high circulating serum 25(OH)D concentration because it is being 
stored in fat compartments.99  One study showed that diet can attenuate the 
seasonal variation in 25(OH)D.100 
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1.2.2.2. Diet 
 Reference values for dietary vitamin D intake were developed by the Food 
and Nutrition Board at the Institute of Medicine of The National Academies.2 
 Dietary vitamin D is provided primarily by foods of animal origin; specifically, 
liver, beef, veal, eggs, dairy products, and some saltwater fish.101 In the United 
States, certain foods like milk, yogurt, orange juice, breads and cereals are 
fortified with vitamin D. For example, milk and orange juice are fortified with 2.5 
micrograms of vitamin D per cup.101  
 Fortified foods provide most of the vitamin D present in the American diet.102 
Low dairy intake has been linked with an increased risk of vitamin D 
deficiency.103,104 Serum 25(OH)D is higher among vitamin supplement pill users 
than nonusers.88,105-109 When sunlight is not successful on its own, diet and 
supplementation can help people achieve adequate 25(OH)D 
concentration.85,87,110-113 The results of a published randomized controlled trial 
study suggest that vitamin D supplementation may be more effective than 
sunlight at achieving serum 25(OH)D concentration goals.114     
 
1.2.4  Measurement of vitamin D 
 
1.2.4.1  Food-frequency questionnaire 
 Food-frequency questionnaires are a common method of dietary assessment 
in epidemiologic studies. Dietary intake of vitamin D in relation to diabetes has 
been assessed in well-known cohorts including Nurses’ Health Study115, 
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Women’s Health Initiative116, Framingham Offspring Study117, Health 
Professionals Follow-Up Study118, and NHANES.119 For example, in the Nurses’ 
Health Study, dietary intake of vitamin D and calcium were assessed with a semi-
quantitative validated food frequency questionnaire in 1980, 1984, 1986, 1990, 
1994, and 1998.115 Dietary intake of vitamin D and calcium was calculated by 
multiplying the frequency of consumption of each food item with the nutrient 
content of each item. Furthermore, multivitamin intake was combined with the 
dietary intake estimates to yield total intakes of vitamin D and calcium. Although 
vitamin D intake may predict serum 25(OH)D concentration2, there are many 
other predictors including age, gender, skin color, sunlight exposure, and BMI. 
Even then, in a carefully designed model, only 26% of the variance in serum 
25(OH)D concentration was explained by predictors.117 This suggests that, if 
available, serum 25(OH)D concentration should be used to assess vitamin D 
status.  
 
1.2.4.2  Serum 25(OH)D concentration 
 25(OH)D concentration in serum is a marker of vitamin D nutriture and 
indicator of biologically available vitamin D. Moreover, it is generally agreed that 
25(OH)D concentration reflects total intake of vitamin D from cutaneous 
synthesis and dietary intake.120,121 Therefore, serum 25(OH)D concentration may 
function as a biomarker of exposure and a reflection of the supply of vitamin D in 
the body. In addition, 25(OH)D has a fairly long circulating half-life of 15 days.122 
1,25(OH)2D has a half-life of about 15 hours122 making it a less useful indicator of 
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vitamin D status.  For these reasons, 25(OH)D is generally agreed to be the best 
marker of vitamin D status.86  
 
1.2.5 Serum 25(OH)D concentration and vitamin D status 
 Vitamin D status is difficult to assess because there is disagreement about 
what 25(OH)D concentration corresponds to given vitamin D status. However, 
recommendations have been made by various researchers/groups and these 
findings have been summarized in Table 1-1. In general, there is very little 
agreement among the researchers/groups regarding vitamin D status based on a 
given 25(OH)D concentration. At the extremes, there is agreement that a 
25(OH)D concentration less than 5 ng/mL and greater than 100 ng/mL is vitamin 
D deficient and excessive/toxic, respectively. However, there is minimal overlap 
between the concentration of 25(OH)D that defines vitamin D sufficiency, 
deficiency, inadequacy, and even harm.  
 
 Included in the Institute of Medicine (IOM) report on dietary reference intakes 
for calcium and vitamin D published in November 2010 were four categories of 
vitamin D status based on serum 25(OH)D: deficiency(<12 ng/mL), 
inadequacy(12–19 ng/mL), sufficiency(20–50 ng/mL), and possible harm (>50 
ng/mL).2 Using these definitions, a data brief was released which found that of 
the United States population from 2001-2006, 8% were at risk of deficiency, 24% 
were at risk of inadequacy, 67% were sufficient, and 1% were in a possibly 
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harmful range.123 Further information regarding how 25(OH)D concentration is 
distributed based on diabetes status may also have public health significance.   
 
1.2.6 Serum 25(OH)D analytical issues 
 Another complication in assessing vitamin D status is the actual 
measurement of serum 25(OH)D concentration itself. 25(OH)D exists in two 
forms, 25(OH)D2 and 25(OH)D3,which all assays cannot easily distinguish. 
Considerable variability exists among the various assays available and among 
laboratories that conduct the analyses.2,124-127 Therefore, compared with the 
actual concentration of 25(OH)D in a sample of blood serum, a falsely low or 
falsely high value may be obtained depending on the assay or laboratory used.128 
A standard reference material for 25(OH)D became available in July 2009 that 
permits standardization of values across laboratories and may improve method-
related variability for the future.129  
 The types of analytical methods for measuring 25(OH)D can generally fall 
under the categories of protein-binding assays (e.g. radioimmunoassay) or 
chemical assays (e.g. liquid chromatography coupled with mass spectrometry). 
NHANES 1988-2006 used the DiaSorin radioimmunoassay for 25(OH)D 
measurement. A roundtable summary by NHANES indicates that the group is 
moving towards liquid chromatography tandem mass spectrometry for NHANES 
2007 and beyond. The evidence is not clear that liquid chromatography will be a 
better option but NHANES 2001-2004 has had issues with assay drifts; in 
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November 2010, these numbers were readjusted and NHANES urges data 
analysts to use these updated values.130 
 
1.3.  Potential mechanisms for effect of vitamin D on type 2 diabetes risk 
 Vitamin D is suspected to play a role in many of the mechanisms related to 
the physiology of type 2 diabetes. Although these mechanisms are not well 
understood, pathways by which vitamin D may increases risk of diabetes include 
impaired pancreatic β-cell function, insulin resistance and systemic inflammation.  
1.3.1 Pancreatic β-cell dysfunction 
 Evidence suggesting that vitamin D has a direct effect on insulin secretion is 
important because insulin resistance is one of the defining features of type 2 
diabetes. 1,25(OH)2D binds the specific β-cell vitamin D receptors.131 There is 
also evidence that the 1-α-hydroxylase enzyme, which activates 25(OH)D, is also 
expressed in β-cells.132 Zeitz et al. showed that there was impaired insulin 
secretory response in mice lacking functional vitamin D receptors.133 There was 
also shown to be transcriptional activation of the human insulin gene by 
1,25(OH)2D supporting the notion that vitamin D impacts insulin production.134 
Finally, supplementation with vitamin D in animals was found to restore insulin 
secretion in 5 different studies.135-139  
 There is also some evidence that vitamin D has an indirect effect on insulin 
secretion, mainly through its interaction with calcium. It is well understood that 
vitamin D is involved in regulation of extracellular calcium. It is also involved in 
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maintenance of calcium flux in the pancreatic β-cell through its regulation of 
calbindin, a cytosolic calcium-binding protein.140  Insulin secretion was found to 
be calcium-dependent based on support from in vitro studies conducted in rabbit 
pancreata.141  
 In observational studies, the evidence supporting an association between 
25(OH)D and pancreatic β-cell function has been moderate in strength. In a 
cross-sectional study with 712 subjects at risk for type 2 diabetes, serum 
25(OH)D was found to be independently associated with pancreatic β-cell 
dysfunction after adjustment for sociodemographic factors, physical activity, 
supplement use, parathyroid hormone, and BMI.142 A different cross-sectional 
study among 126 healthy, glucose tolerant subjects found a subtle negative 
effect of low 25(OH)D on β-cell function.77 Although the researchers found no 
independent effect of 25(OH)D on the measured β-cell function (first-phase 
insulin response and second-phase insulin response), they believe that because 
of the relation of 25(OH)D to plasma glucose concentration, β-cells were 
compensating for insulin resistance to maintain plasma glucose concentrations 
within a small range. Furthermore, if 25(OH)D had no effect on β-cell function, 
then there would have been no relation between plasma glucose and 25(OH)D. 
Researchers in a different study found that 25(OH)D is associated with β-cell 
function after adjustment for traditional risk factors for type 2 diabetes except for 
BMI.143 Because BMI is so strongly associated with 25(OH)D and type 2 
diabetes, it is reasonable to observe that the association was weakened. In the 
most recent published report on this topic, serum concentration of 25(OH)D was 
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associated with adjusted β-cell function in 150 healthy adults after adjustment for 
age, gender, BMI, physical activity, ethnicity, and season.144 
1.3.2  Insulin resistance 
 There is evidence that vitamin D directly causes an improvement in insulin 
action by stimulating the expression of the insulin receptor which results in better 
insulin responsiveness for glucose transport.145 This was supported by in vitro 
studies when tested in human promonocytic cells. Other evidence supporting the 
role of vitamin D in insulin action includes the presence of vitamin D receptors in 
skeletal muscle 146 and an inverse association between 25(OH)D concentration 
and sarcopenia (loss of skeletal muscle mass).147 Vitamin D has been found to 
indirectly improve insulin action because of its association with calcium. In vitro 
and in vivo studies have shown that calcium is essential for insulin-mediated 
processes in insulin responsive tissues such as skeletal muscle and adipose 
tissue.148-150  
 Observational studies have consistently shown that 25(OH)D is related to 
insulin resistance.77,142,143,151-157 The exception is one cross-sectional study 
where adjustment for BMI attenuated the association and produced a non-
statistically significant effect estimate.143 In a recent report, serum concentration 
of 25(OH)D was associated with insulin sensitivity in healthy adults after 
adjustment for age, gender, BMI, physical activity, ethnicity, and season.144 
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1.3.3 Systemic inflammation 
 There is experimental support for the hypothesis that vitamin D improves 
systematic inflammation. The presence of vitamin D receptors on inflammatory 
cells suggests that there is a potential role for vitamin D in inflammation.158 
Systemic inflammation is related to cytokine levels which may play a role in β-cell 
dysfunction by triggering β-cell apoptosis (programmed cell death). Vitamin D 
may improve insulin sensitivity and promote β-cell survival by directly impacting 
the production and effects of cytokines. Vitamin D was found to interact with 
vitamin D response elements in the promoter region of cytokine genes to impede 
production. 159-161 Vitamin D was also found to down-regulate the activation of a 
nuclear factor purported to play a role in insulin resistance.162 Furthermore, it has 
been found that changes in blood concentration of calcium (which is closely 
linked with vitamin D concentration) can impact the survival of a cell through 
cytokine signaling.163  Recent evidence indicates that vitamin D may inhibit 
monocyte and macrophage proinflammatory cytokine production by targeting 
MAPK phosphatase-1.164 The researchers sought to better understand the 
mechanism by which vitamin D reduces inflammation. They investigated the 
inhibitory effects of serum 25(OH)D3 and 1,25(OH)2D3 on the inflammatory 
response in monocytes from humans. They observed that vitamin D inhibited 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) production by human 
monocytes. Furthermore, upon treatment with vitamin D, expression of MAPK 
phosphatase-1 was up-regulated in monocytes. This investigation was able to 
identify a new pathway by which vitamin D inhibits inflammation. 
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 There have been few observational studies conducted examining the 
association between 25(OH)D and inflammation in adults and the relationship is 
not yet clear (Table 1-2). In a cross-sectional study among 147 obese patients, 
serum 25(OH)D was inversely associated with several inflammatory markers, C-
reactive protein (CRP), IL-6, and TNF-α, in the final model after adjustment for 
BMI, body fat, and body fat percentage.165 Adjustment for demographic factors 
likely would have attenuated the effect. In a study among 61 patients on 
hemodialysis, inflammatory marker concentration among those who were 
25(OH)D deficient (<30 ng/mL) were compared to those who had normal 
25(OH)D concentration (>30 ng/mL).166 The proportion of subjects with high 
inflammation (high-sensitive CRP >3 mg/L) among those with 25(OH)D 
deficiency was higher compared to 25(OH)D normal subjects (73% versus 43%, 
p<0.05). However, when high-sensitive CRP was continuous there was not a 
statistically significant difference across the 25(OH)D groups (p=0.13). The 
former comparison where there was a statistically significant difference may be 
clinically meaningful. In a study among 109 Chinese patients with type 2 
diabetes, vitamin D supplementation among those with 25(OH)D was not 
associated with ferritin and high-sensitivity CRP.167 However, since these 
patients had type 2 diabetes which is often correlated with inflammation, 168,169 it 
is possible that vitamin D had less of an impact because systemic inflammation 
was already present. These studies likely had limited external validity since the 
participants were sick patients who are not representative of the general 
population. 
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 Recent studies also support that 25(OH)D is associated with inflammation. 
For example, hemodialysis patients not under vitamin D receptor agonist 
treatment had serum concentrations of 25(OH)D, CRP, and IL-6 measured by 
immunoassays. 170 25(OH)D was inversely correlated with CRP and IL-6, 
although these correlations don’t represent independent effects since adjustment 
for confounders was ignored. Furthermore, hemodialysis patients have limited 
generalizeability since they are likely older and less healthy than the general 
population. Evidence from an analysis of cross-sectional data from NHANES 
indicates that 25(OH)D is inversely associated with CRP when 25(OH)D< 21 
ng/mL. 171 The association between 25(OH)D and CRP is positive when 25(OH)D 
≥ 21 ng/mL. However, the consistency of this positive association was not 
examined by subgroups. Furthermore, the association of 25(OH)D was not 
examined with fibrinogen or homocysteine, other biomarkers of inflammation 
available in the dataset. Stronger evidence for an association between 25(OH)D 
comes from a randomized controlled trial where patients were randomized to 
receive 100,000 units of oral vitamin D3 or placebo at baseline, 2 months and 4 
months.172 When measured at 6 months, CRP showed a decline in the 
intervention group compared to placebo (-1.3 vs. 2.0 mg/dL, p=0.03). Although 
the study design was strong, the results may have limited internal validity since 
there was no adjustment for confounding; furthermore,  the study may have 
limited external validity since the study sample comprised elderly patients with a 
history of myocardial infarction.  
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 Results from the MONICA/Cooperative Health Research in the Region of 
Augsburg study indicate that inflammation mediates the association between 
25(OH)D and incident type 2 diabetes.173 The researchers calculated an 
independent association between 25(OH)D and incident type 2 diabetes after full 
covariate adjustment (HR=0.63, 95% CI: 0.44-0.90). Additional adjustment for 
inflammatory markers including CRP, IL-6, soluble intercellular adhesion 
molecule-1, and interferon-γ-inducible protein-10 attenuated the association by 
16%. Therefore, the researchers concluded that 16% of the association between 
25(OH)D and diabetes was mediated by inflammation. 
1.4. Evidence from human studies 
 Many human studies have evaluated the association between 25(OH)D and 
type 2 diabetes or prediabetes. To identify these publications, searches of 
Medline and Web of Science were conducted for English-language literature 
between January 1, 1980 and April 15, 2012. Searches were conducted using 
the following terms: diabetes, hyperglycemia, prediabetes, impaired fasting 
glucose, impaired glucose tolerance, 25-hydroxyvitamin D and 25(OH)D. All 
records were downloaded and imported into Endnote X5, and duplicate records 
were removed. A total of 917 abstracts were identified from searches (528 from 
Medline and 389 from Web of Science). Articles were then manually screened 
and excluded if any of the following criteria applied: 1) failure to focus on 
25(OH)D and type 2 diabetes or prediabetes; 2) study sample of children; and, 3) 
outcomes of gestational diabetes or type 1 diabetes. Furthermore, with the 
exception of randomized controlled trials, only studies where vitamin D status 
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was assessed through serum 25(OH)D concentration were kept. Additional 
publications were identified through citations from recovered articles and 
systemic review manuscripts. 38 articles were identified and reviewed.  
1.4.1. Cross-sectional studies  
 NHANES data has generally indicated that 25(OH)D is associated with 
diabetes in adults.157,174,175 Kositsawat et al. found that 25(OH)D was inversely 
associated with hemoglobin A1c (HbA1c) in participants between 35-74 years of 
age in NHANES 2003-2006.174 Likewise, Zhao et al. found that among 
participants without physician-diagnosed diabetes, biomarkers of insulin 
resistance and glycemia (HbA1c, fasting hyperglycemia, and 2-hour 
hyperglycemia) decreased linearly across quintiles of 25(OH)D in NHANES 
2003-2006.175 The association remained in all 3 biomarkers after adjustment for 
age, sex, race, education, smoking, alcohol, and physical activity. However, after 
adjustment for abdominal obesity, fasting hyperglycemia was no longer 
significant. Scragg et al. found an inverse association between serum 25(OH)D 
concentration and diabetes in an analysis of NHANES III (1988-1994).157 
 Serum 25(OH)D values from NHANES surveys have been affected by 
fluctuations in assay performance due to measurement procedure bias. In 
November 2010, The National Center for Health Statistics (NCHS) updated 
serum 25(OH)D data files, replacing previous data files for public use.176 In the 
advisory note, the NCHS specifically recommended that the adjusted data rather 
than previously available unadjusted data be used for all analyses of serum 
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25(OH)D concentrations for NHANES 2001–2006 (Appendix B). Thus, previously 
reported associations in adults using the unadjusted serum 25(OH)D data from 
the 3 cycles conducted between 2001-2006 were likely biased.174,175  
 
Other Data Sources 
 Evidence for an inverse association between serum 25(OH)D and type 2 
diabetes has been derived from many cross-sectional studies.66,157,177-180 
However, the results have not been internally and externally consistent. 
157,177,181,182 Depending on the outcome measure, study results varied within the 
same study. For example, in the Baynes et al. study, 177 serum 25(OH)D was 
found to be associated with 1-hour glucose after a standard 75-g oral glucose 
tolerance test (OGTT) but not fasting plasma glucose (FPG); OGTT and FPG are 
measures of glycemia which are often used as proxies for glucose intolerance.  
 A cross-sectional study conducted at a geriatric clinic did not find a 
statistically significant association between 25(OH)D and diabetes.182 However, 
the analysis was likely underpowered since 78 patients were included. Moreover, 
since the patients were elderly, it may indicate that age is an effect modifier. 
Results from a population survey in England suggest that 25(OH)D was 
independently associated with HbA1c after adjustment for age, gender, social 
class, season, vitamin supplements, and physical health status.180 A cross-
sectional study among patients from an diabetes clinic found that serum 
25(OH)D was associated with HbA1c.183 However, no attempt was made to 
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control for treated diabetes patients who likely have lower HbA1c values. 
Although it is stated that the sample had a high HbA1c (mean±SD=7.8±1.6), the 
authors do not report the distribution or median so it is possible that few poorly 
controlled diabetes patients skewed the values to the higher end.  
 Results from a cross-sectional analysis of the Tromsø Study indicate that 
high serum 25(OH)D concentration is associated with lower HbA1c.184 Among 
8,643 participants without diabetes between 30-87 years of age, r= -0.07, and 
this correlation coefficient remained significant after adjustment for age, gender, 
season, BMI, physical activity, and serum triglycerides. Recent findings from the 
Kuopio Ischaemic Heart Disease Risk Factor Study indicate that serum 25(OH)D 
concentration was inversely associated with OGTT 2-hour glucose concentration 
after adjustment for age, gender and examination year. 185 However, 
confounders that were not adjusted for include season, race, physical activity, 
and obesity. The results of reviewed cross-sectional studies are summarized in 
Table 1-3.  
1.4.2. Case-control studies  
 Case-control studies have generally been consistent in finding an association 
between serum 25(OH)D concentration and type 2 diabetes (Table 1-4). 186-195 
Most recent studies have not utilized a case-control design. Patients from a 
diabetes clinic were more likely to have serum 25(OH)D concentration below 20 
ng/mL compared to age- and sex-matched volunteers without diabetes 
(p<0.001).187 These results may have limited generalizeability to individuals with 
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undiagnosed diabetes who are not under the care of a physician. Furthermore, 
analysis of survey data from the British birth cohort indicates that participants 
with HbA1c above 7% had significantly lower serum 25(OH)D concentration 
compared to participants with HbA1c less than or equal to 7%.188  
 Results from a survey from New Zealand indicate that controls were 64% 
less likely than newly detected diabetes cases to have low serum 25(OH)D3 
(OR=0.36, 95%CI: 0.19-0.71).189 This reported association includes adjustment 
for BMI, hypertension, physical activity and serum lipids. It is possible that 
association would have been stronger if both 25(OH)D3 and 25(OH)D2 were 
measured and accounted for in the analysis. Most novel instruments have a 
single 25(OH)D measure which includes 25(OH)D2 and 25(OH)D3. The described 
case-control studies, which all had sufficient power and adequate adjustment for 
confounding, found associations between 25(OH)D and type 2 diabetes.187-189 
1.4.3  Prospective studies 
 Many prospective cohort studies have examined the association between 
25(OH)D and type 2 diabetes (Table 1-5).196-200 In 2007, Mattila et al. conducted 
a prospective cohort study in a sample of 4423 men and women between 40-69 
years of age.197 A significant inverse association was found between serum 
25(OH)D and risk of type 2 diabetes in the initial model adjusted for age, sex, 
and month. However, after full adjustment that included exercise and BMI, the 
association was attenuated and the results were not statistically significant. 
Because exercise may precede BMI in a causal diagram and both are correlated, 
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it would have been of scientific interest to test if the association remained after 
only adjustment for exercise and not BMI. In 2010, Pittas et al. used Nurses’ 
Health Study data to assess the association between 25(OH)D  and newly 
diagnosed diabetes.198 After complete covariate adjustment, higher serum 
25(OH)D concentration was associated with a lower risk of incident type 2 
diabetes. Grimnes et. al found that 25(OH)D was associated with incident type 2 
diabetes after adjustment for age and sex but was attenuated after adjustment 
for BMI199.   
 The Prospective Metabolism and Islet Cell Evaluation Cohort Study indicates 
that higher baseline 25(OH)D concentration predicted lower glycemia, which was 
assessed by area under the glucose curve, in a 3-year time period.201 
Furthermore, higher baseline 25(OH)D predicted improved β-cell function at 
follow-up which supports an etiologic role for vitamin D in diabetes. These 
associations were significant after full covariate adjustment. However, higher 
25(OH)D reduced risk of impaired glucose tolerance in an unadjusted model but 
this association was not statistically significant after adjustment for BMI 
(OR=0.78, 95% CI:0.59-1.02). 
 In a recent prospective study, men in the highest quartile of 25(OH)D 
concentration who had prediabetes at baseline had a reduced risk of developing 
diabetes 10 years later (OR=0.52, 95% CI: 0.30, 0.90).202 Furthermore, the same 
association was not significant among those with normal glucose tolerance at 
baseline. This suggests that high serum 25(OH)D may only be beneficial in men 
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with impaired glucose tolerance and not those with adequate glucose 
homeostasis.  
   1.4.4  Effect modification of covariates on the association between 
25(OH)D and diabetes 
 
1.4.4.1 Interaction by gender 
 Several prospective studies indicate that there is heterogeneity by gender on 
the association between serum 25(OH)D concentration and risk of diabetes. 
116,196,200,202  In a pooled-analysis of nested-case control studies conducted in 
Finland, there was a significant association between 25(OH)D and incident 
diabetes among middle-age men; however, a significant association was not 
found among women.196 Men had higher serum 25(OH)D concentrations than 
women and showed a reduced risk of diabetes in their highest 25(OH)D quartile. 
In a recent prospective study, men in the highest quartile of 25(OH)D 
concentration who had prediabetes at baseline had a reduced risk of developing 
diabetes 10 years later.202 However, the association was not significant in 
women. 
  In a highly powered, post-hoc analysis of data from the Women’s Health 
Initiative, Robinson et al. did not find an association between 25(OH)D and 
incident diabetes in postmenopausal women.200 Regardless of the utilized 
cutpoints (quartiles or clinical) or as a continuous variable, 25(OH)D 
concentration was not associated with incident diabetes. Furthermore, there was 
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no association in subgroups based on BMI or race/ethnicity. Assessment of 
significance in age subgroups in a meaningful way would have been difficult 
since most participants were elderly (mean age=66 years).  
 In an interventional trial from the Women’s Health Initiative, supplementation 
with calcium and vitamin D3 did not lower the risk of incident diabetes in elderly 
women.116 Women were followed for a median of 7 years, and the hazard ratio 
for incident diabetes was not significant based on intention to treat (HR=1.01, 
95% CI: 0.94-1.10). Moreover, the result remained the same in subgroup 
analyses and efficacy analyses accounting for non-adherence. In the studies 
conducted by the Women’s Health Initiative, the role of sex hormones or the 
possibility than women are less sensitive to vitamin D cannot be excluded. 
Furthermore,, age may have played a role since the cohort is made up of 
postmenopausal women.  
1.4.4.2 Interaction by age 
 Previous studies that suggest interaction by age were conducted in 
women.116,200 Therefore, it is difficult to separate the effects of gender and age. 
Since the Nurses’ Health Study features middle-aged women, and an analysis 
found that vitamin D and calcium intake did reduce diabetes risk115, there is a 
possibility of combined age and sex interaction. Recent results from the 
MONICA/KORA Augsburg study support this hypothesis and indicate that women 
above 52 years of age did not experience a protective effect from 25(OH)D in 
regards to risk of diabetes. However, women below 52 years of age did benefit 
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from high 25(OH)D. Moreover, the 25(OH)D*sex*age-group third-order 
interaction was highly statistically significant.  
1.4.4.3 Interaction by obesity 
 Obesity may modify the association between 25(OH)D concentration and risk 
of type 2 diabetes. Many pathways biologically relevant to vitamin D  are for 
obesity as well, given that obesity is a risk factor for type 2 diabetes13,28,203, 
insulin resistance29,204,205, and low serum 25(OH)D.11,188,206,207 It has been 
demonstrated that the association between serum 25(OH)D concentration and 
HbA1c was stronger in British adults that had a high BMI compared to adults that 
had a low BMI after full covariate adjustment188. In a study among participants 
from a university campus, the association of serum 25(OH)D concentration with 
insulin sensitivity was found to be stronger in overweight persons than in normal 
weight persons.208 However, it is difficult to generalize their study results due to 
the limited age range, racial diversity, and fact that the participants in the study 
were not obese. 
1.4.4.4 Interaction by race/ethnicity 
 Diabetes is more prevalent in African Americans than whites.209 African 
Americans tend to have lower 25(OH)D concentration than whites.94,97,210 
Differences in vitamin D binding protein genes211, obesity212, lower vitamin D 
intake through diet213, and skin color214,215  may partially explain differences in 
25(OH)D. Most observational studies that have examined the association 
between 25(OH)D concentration and type 2 diabetes did not include enough 
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African American participants to conduct analyses stratified by race/ethnicity. 
NHANES is an important exception because this survey aims to oversample 
African American participants. 
 A study by Scragg et al. which analyzed data from NHANES III found that the 
association between 25(OH)D and type 2 diabetes varied by race/ethnicity.157 
The risk of type 2 diabetes was found to be inversely associated with 25(OH)D in 
the highest 25(OH)D quartile compared to the lowest for non-Hispanic whites 
(OR=0.25, 95% CI: 0.11–0.60) and Mexican Americans (OR=0.17, 95% CI: 
0.08–0.37) but not non-Hispanic blacks. Decreased sensitivity to vitamin D may 
explain part of this relationship. It is also important to note that non-Hispanic 
whites and Mexican Americans with 25(OH)D concentrations ≥ 16 ng/mL had a 
decrease in diabetes prevalence of 65% and 48%, respectively, but there was no 
evidence of a similar benefit for African Americans. In contrast, a different study 
using NHANES data found an association between 25(OH)D concentration and 
markers of insulin resistance that did not vary across race/ethnicity groups 
neither after nor before adjustment for hypothesized confounders.175 
Understanding if 25(OH)D variations explain any of the racial disparities in 
diabetes is a good public health question and merits further research with current 
data.  
 A recent randomized controlled trial found that vitamin D supplementation 
among African Americans did not improve glycemic control over 3 months. 
Overweight or obese African American participants with prediabetes were 
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assigned to the placebo or intervention group, where the intervention group 
received 4000 IU/day of vitamin D3. Serum 25(OH)D was approximately 16 
ng/mL in both groups at baseline and increased to 32 ng/mL after 3 months for 
the intervention group. Although there was an increase in 25(OH)D, there was no 
improvement in glycemia which suggests these individuals had a reduced 
sensitivity to vitamin D. Longer follow-up time may have resulted in improved 
glycemic control.  
 
1.4.5  Association between serum 25(OH)D concentration and prediabetes 
 Analysis of the NHANES III data has shown that low serum 25(OH)D 
concentration was associated with prediabetes after adjustment for known 
confounders.216 Subgroup analyses indicate that the association remained 
significant when stratified by gender, BMI, and hypertension categories. This 
study was one of the first to examine the association between 25(OH)D and 
prediabetes, where the outcome was defined based on the most recent American 
Diabetes Association (ADA) guidelines.217 
 In an analysis of cross-sectional data, participants with high serum 
concentration of 25(OH)D showed a reduced prevalence of prediabetes 
compared to individuals with low serum 25(OH)D concentration.202 Every 4 
ng/mL increase in serum concentration of 25(OH)D reduced the association with 
prediabetes by 18% (p=0.001) in men and 11% (p=0.051) in women. However, it 
is not clear why the researchers classified prediabetes based on the 2004 
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American Diabetes Association guidelines when the 2010 version was available 
for over one year before the report was submitted for publication. Furthermore, 
the authors don’t specify the higher cutpoint for FPG to classify prediabetes; it is 
unclear if the cutpoint is above 7.0 mmol/L which is the range of type 2 diabetes 
diagnosis. Therefore, there may be outcome misclassification.  
 Lastly, a recent cross-sectional study has found that among healthy non-
Hispanic White adults, 25(OH)D below the 75th percentile in their sample was 
associated with an increased odds of prediabetes compared to participants 
above the 75th percentile of 25(OH)D concentration.218 However, definition of 
prediabetes was inconsistent with recent ADA guidelines since it was only based 
on FPG, therefore, information from the OGTT and HbA1c tests were ignored. In 
addition, covariate adjustment was inadequate since models only included age, 
gender and BMI while there are other variables available to the researchers that 
were associated with 25(OH)D and prediabetes which were excluded. This report 
and another cross-sectional study216 also used odds ratios to estimate the 
association between 25(OH)D and prediabetes although prediabetes is known to 
have a high prevalence. Correction of the odds ratio using the Zhang and Yu 
method219 or calculation of a relative risk likely would have attenuated results 
since the odds ratio overestimates the relative risk for common outcomes. 
1.4.6 Randomized controlled trials 
 The majority of randomized controlled trials that have been conducted to 
date in regards to vitamin d supplementation and risk of type 2 diabetes have not 
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focused on 25(OH)D status and future risk of diabetes.8 Previous studies have 
been off topic or were problematic because of focus on glycemic control in 
patients with physician-diagnosed diabetes220-222 or because they were post hoc 
analyses116,223 or trials with high dropout rates.220-222,224-226  
 Recent results from the Calcium and Vitamin D for Diabetes Mellitus 
randomized controlled trial indicate supplementation with 2000 IU once daily of 
cholecalciferol (vitamin D3) improved glucose homeostasis in adults at risk for 
diabetes.227 Participants were adults with prediabetes over the age of 40 years 
with a BMI>25 kg/m2. Vitamin D was assessed through measurement of 
25(OH)D concentration at baseline and 16 weeks after baseline. HbA1c 
decreased less in the group that received vitamin D3 than the group that did not 
receive vitamin D3 (p=0.08). After excluding two data points where the HbA1c 
change was greater than 0.8% in the control group, the decrease became 
significant (p=0.02). Although a 0.8% change in HbA1c represents a large 
change, it is realistic so it is unclear why these points were removed. Calcium on 
its own did not attenuate HbA1c. Furthermore, there was no interaction observed 
with vitamin D and calcium in this study on reducing HbA1c. Issues with this 
study include small sample size and poor justification regarding removal of 
outliers. However, this recent study is one of the stronger to date and supports 
25(OH)D predicting future risk of type 2 diabetes.  
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1.6 Tables and Figures 
Table 1-1 Vitamin D Status Based on Serum 25(OH)D Concentration 
 
  
 Vitamin D Status 
25(OH)D 
(ng/mL)  Zitterman228, 2003 
 
Grant et al.67, 2005 
Institute of 
Medicine2, 2010 
<5 Deficiency Deficiency Deficiency 
5-11.9 Insufficiency Deficiency Deficiency 
12-19.9 Insufficiency Deficiency Inadequacy 
20-31.9 Hypovitaminosis Insufficiency Sufficiency 
32-39.9 Hypovitaminosis Sufficiency Sufficiency 
40-49.9 Sufficiency Sufficiency Sufficiency 
50-53.9 Sufficiency Sufficiency Possibly harmful 
54-99.9 Sufficiency Sufficiency Possibly harmful 
100-149.9 Toxicity Excess Possibly harmful 
>150 Toxicity Intoxication Possibly harmful 
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Table 1-2 Reviewed studies on association between serum 25(OH)D 
concentration and inflammation in adults 
 
 
First 
authorref,year, 
cohort 
[country] 
Age (yrs). 
sex Outcome  n Main study results Adjustments 
Witham172, 
2012, Patients 
with history of 
MI [United 
Kingdom] 
μ=66, M/F CRP 75 CRP decreased after 
supplementation with 
vitamin D, Baseline 
25(OH)D 
concentration 
<20ng/mL 
None 
Amer171, 2012, 
NHANES [USA] 
μ =45.3 CRP 15,167 CRP negatively 
associated with 
25(OH)D below 21 
ng/mL, positive when 
above 21 ng/mL 
Age, gender, 
race, central 
obesity, 
cholesterol, 
glucose, 
smoking, white 
blood cell 
count, GFR 
Eleftheriadis170, 
2012, 
Hemodialysis 
patients 
[Greece] 
μ=62.8, 
M/F 
CRP and 
IL-6 
33 25(OH)D inversely 
correlated with CRP 
and IL-6 
None 
Bellia165, 2011, 
Obese 
individuals [Italy] 
<50, M/F TNF-α, IL-
6, 
fibrinogen, 
hs-CRP 
147 25(OH)D inversely 
associated with hs-
CRP, IL-6, and TNF-
α 
Age, gender, 
season, BMI, 
total body fat 
and truncal 
body fat 
Bucharles166, 
2011, 
Hemodialysis 
patients [Brazil] 
μ=56, M/F hs-CRP, 
IL-6 
61 High Hs-CRP 
(>3mg/L) was 
associated with low 
25(OH)D 
None 
Luo167, 2009, 
Type 2 diabetes 
patients [China] 
>50, M/F hs-CRP, 
ferritin 
109 25(OH)D not 
associated with hs-
CRP or ferritin 
None 
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Peterson229, 
2008, Healthy 
women [USA] 
25-82, 
M/F 
TNF-α, IL-
6, IL-10, 
CRP 
69 TNF-α was inversely 
associated with 
25(OH)D 
Body fat mass, 
menopausal 
status, age 
 
TNF-α: Tumor necrosis factor-α, IL-6: Interleukin 6, hs-CRP: high-sensitivity C-reactive 
protein, CRP: C-reactive protein, MI: Myocardial infarction, GFR: Glomerular filtration 
rate 
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Table 1-3 Reviewed cross-sectional studies on association between serum 
25(OH)D concentration and type 2 diabetes mellitus/prediabetes in adults 
 
 
First 
authorref,year, 
cohort 
[country] 
Age 
(yrs), 
Sex Outcome n 
25(OH)D, 
range or 
comparison
* 
Main study 
results Adjustments 
Shankar216, 
2011, NHANES 
1988-1994 
[USA] 
≥20, 
M/F 
Pre-DM  12,719 Quartiles [Q1 
vs.Q4] 
OR=1.47, 
95%CI (1.16-
1.85) 
Age, sex, race, 
season, geographic 
region, smoking, 
alcohol intake, BMI, 
outdoor physical 
activity, milk 
consumption, 
dietary vitamin D, 
blood pressure, 
serum cholesterol, 
CRP, GFR 
Deleskog202, 
2012, Stockholm 
Diabetes 
Prevention 
Program 
[Sweden] 
35-56, 
M/F 
Pre-DM 2,055 Quartiles[Q4 
vs. Q1] 
OR=0.49, 
95%CI(0.34-
0.72)  
Age, BMI, Family 
history of diabetes, 
physical activity, 
blood pressure 
Scragg157, 2004, 
NHANES 1988-
1994 [USA] 
≥20, 
M/F 
type 2 
diabetes  
6,228 Quartiles [Q4 
vs. Q1] 
Whites, 
OR=0.25(0.11-
0.60); 
Mexican, 
OR=0.17(0.08-
0.37); 
Blacks, 
OR=0.76 (0.18-
3.18) 
Age, sex, BMI, 
leisure activity, 
quarter of year 
Kositsawat174, 
2010, NHANES 
2003-06 [USA] 
18-34, 
M/F 
HbA1c 3,525 3-72 ng/mL p-value = 0.40 Age, sex, race, 
BMI, self-reported 
diabetes, physical 
activity, dietary 
supplement use, 
PTH 
35-74, 
M/F 
5,138 p-value = 
0.0045 
≥75, 1,110 p-value = 0.63 
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M/F 
Zhao175, 2010, 
NHANES 2003-
2006 [USA] 
≥20, 
M/F 
Indicators 
of insulin 
resistanc
e 
3,206 Quintiles [Q5 
vs. Q1] 
Hyperinsulinem
ia, high HOMA-
IR, high 
HbA1c,and 2-
hour 
hyperglycemia 
were 
associated with 
low 25(OH)D 
after 
adjustment 
Age, sex, 
race/ethnicity, 
education, 
smoking, physical 
activity, alcohol 
drinking, BMI, 
abdominal obesity, 
and serum calcium 
concentrations 
Ford179, 2005, 
NHANES 1988-
1994, 1999-2000 
[USA] 
>20, 
M/F 
type 2 
diabetes  
8,241 >38 ng/mL 
vs. <19 
ng/mL  
OR=0.46, 95% 
CI: (0.32-0.67) 
Age, sex, race, 
exercise, smoking, 
alcohol, diet, 
supplement use, 
cholesterol, CRP, 
education, season 
Dalgard178, 
2011, 
Septuagenarians 
[Denmark] 
70-74, 
M/F 
type 2 
diabetes  
668 <20 ng/mL 
vs. >20 
ng/mL  
OR=1.67 , 95% 
CI: (1.11-2.50) 
BMI, sex, exposure 
to polychlorinated 
biphenyls, serum 
triglyceride 
concentration, 
serum HDL 
concentration, 
smoking status, 
and month of blood 
sampling 
Snijder181, 
Longitudinal 
Aging Study 
Amsterdam, 
2005 
[Netherlands] 
μ=75, 
M/F 
type 2 
diabetes  
1235 <10 ng/mL 
vs. ≥30 
ng/mL  
OR=1.23, 95% 
CI:  (0.50,3.02) 
Age, sex, waist-to-
hip ratio, exercise, 
smoking, alcohol, 
region, season 
Choi66, 2011, 
Fourth Korea 
NHANES, 
[Korea] 
>20, 
M/F 
type 2 
diabetes  
5787 <10 ng/mL 
vs. ≥30 
ng/mL 
OR= 1.73, 95% 
CI:  (1.09-2.74) 
Age, sex, season, 
current smoking, 
alcohol drinking, 
regular walking, 
regular exercise, 
region, BMI and 
waist 
    10 to <20 
ng/mL vs. 
≥30 ng/mL 
OR = 1.30, 
95% CI:  (0.91-
1.84)  
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    20 to <30 
ng/mL vs. 
≥30 ng/mL 
OR= 1.40, 95% 
CI:  (0.99-1.98) 
circumference 
Hidayat182, 
Geriatric 
patients, 2010, 
[Indonesia] 
>60, 
M/F 
type 2 
diabetes  
78 >20 ng/mL 
vs. <20 
ng/mL  
OR = 0.8 , 95% 
CI: (0.5-1.3)  
Sex, BMI, sun 
protector  
Baynes177, 1997, 
Elderly men, [the 
Netherlands] 
μ=76, M FPG, 1 h 
glu, 2 h 
glu 
142 1-75 ng/mL 25(OH)D 
associated with 
1 hour plasma 
glucose (r=-
.23) but not 
FPG or 2 hour 
glucose 
Age, BMI, physical 
activity, month of 
sampling, cigarette 
smoking, and 
alcohol intake 
Hirani180, 2011, 
Health Survey 
for England, 
[England] 
65+, 
M/F 
Hemoglo
bin A1c 
2038 1-10 ng/mL OR=2.34, 
95%CI: (1.14-
4.80) 
Age, gender, social 
class, season, 
vitamin 
supplements, and 
physical health 
status 
Meguro183, 2011, 
Diabetes 
patients, [Japan] 
μ =64.5, 
M  
Hemoglo
bin A1c 
106 3-51 ng/mL β=0.19 
(p=0.02) 
Albumin creatinine 
ratio, glomerular 
filtration rate, BMI, 
cholinesterase 
Hurskainen185, 
2012, Kuopio 
Ischaemic Heart 
Disease Risk 
Factor Study, 
[Finland] 
53-73, 
M/F 
type 2 
diabetes 
1756 3-49 ng/mL 
(Q3 vs. Q1) 
RR=1.44, 95% 
CI(0.96-2.15) 
Age, gender, 
examination 
year/month, BMI, 
waist-to-hip ratio, 
smoking, physical 
activity, intake of 
fruits, berries and 
vegetables, family 
history of diabetes 
  
*Highest/lowest risk category versus reference category 
type 2 diabetes: Type 2 diabetes mellitus, Pre-DM: Prediabetes, CRP: C-reactive 
protein, GFR: Glomerular filtration rate, HbA1c: Hemoglobin HbA1c, PTH: Parathyroid 
hormone, HOMA-IR: Homeostatic model assessment-insulin resistance, FPG: Fasting 
plasma glucose, 1 h glu: 1-hour glucose, 2 h glu: 2-hour glucose 
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Table 1-4 Reviewed case-control studies of association between serum 25(OH)D 
concentration and type 2 diabetes mellitus in adults 
 
 
First authorref, 
year, country 
Age 
(yrs), 
Sex 
Cases, 
sample 
size 
Control 
Group, 
sample 
size 
25(OH)D, 
range or 
comparison* 
Main study 
results 
Adjustments 
Boucher186, 
1995, London 
40-57, 
M/F 
type 2 
diabetes
/IGT, 
n=44 
Age-
,sex-
matche
d, n=15 
28 ng/mL vs. 
30 ng/mL 
(p=0.01) 
Lower 
25(OH)D in 
cases 
compared to 
controls  
None (matched on 
age and sex) 
Ishida230, 1985, 
Japan 
19-80, 
M/F 
type 2 
diabetes
, n=168 
n=78 30 ng/mL vs. 
28 ng/mL 
No difference None 
Cigolini187, 2006, 
Italy 
μ=61, 
M/F 
type 2 
diabetes
, n=459 
Age-
,sex-
matche
d, 
n=459 
20 ng/mL vs. 
24 ng/mL 
(p<0.001) 
Lower 
25(OH)D in 
cases 
compared to 
controls  
None (matched on 
age and sex) 
Hyponnen188, 
2006, Britain 
μ=45, 
M/F 
type 2 
diabetes
, n=125 
Season
-,sex-
matche
d, 
n=7073 
15 ng/mL vs. 
21 ng/mL 
(p<0.001) 
Lower 
25(OH)D in 
cases 
compared to 
controls  
None (matched on 
season and sex) 
Scragg189, 1995, 
New Zealand 
40-64, 
M/F 
Undiagn
osed 
type 2 
diabetes 
cases/I
GT, 
n=238 
Age-
,sex-
,ethnicit
y-,date- 
matche
d, 
n=238 
>33 ng/mL 
vs. ≤27 
ng/mL 
OR=0.36, 
95%CI:0.19-
0.71 
BMI, hypertension, 
physical activity, 
serum lipids  
Christiansen190, 
1982, Denmark 
μ=36, M type 2 
diabetes
, n=26 
Age-
,sex-
matche
d, n=14 
17 ng/mL vs. 
22 ng/mL 
(p<0.05) 
Lower 
25(OH)D in 
cases 
compared to 
controls  
None (matched on 
age and sex) 
Stepan191, 1982, 40-70, type 2 
diabetes
Blood 
donors, 
9 ng/mL vs. 
14 ng/mL 
Lower 
25(OH)D in 
None 
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Czechoslovakia M/F , n=22 n=30 (p<0.05) cases 
compared to 
controls  
Nyomba195, 
1988, Zaire  
34-60, 
M/F 
type 2 
diabetes
, n=20 
n=36 26 ng/mL vs. 
35 ng/mL 
(p<0.001)  
Lower 
25(OH)D in 
cases 
compared to 
controls  
None 
Nyomba195, 
1988, Belgium  
14-63, 
M/F 
type 2 
diabetes
, n=44 
n=26 34 ng/mL vs. 
33 ng/mL  
No difference None 
Pietschmann192, 
1988, Austria  
μ=62, 
M/F 
type 2 
diabetes
, n=38 
Age-
,sex-
matche
d, n=17 
8 ng/mL vs. 
15 ng/mL 
(p<0.001) 
Lower 
25(OH)D in 
cases 
compared to 
controls  
None (matched on 
age and sex) 
Aksoy193, 2000, 
Turkey 
μ=57, 
M/F 
type 2 
diabetes
, n=66 
Season
-
matche
d, n=20 
12 ng/mL vs. 
24 ng/mL 
(p<0.001) 
Lower 
25(OH)D in 
cases 
compared to 
controls  
None (matched on 
season)  
Isaia194, 2001, 
Italy 
μ=57, F type 2 
diabetes
, n=66 
n=66 9 ng/mL vs. 
11 ng/mL 
(p<0.008) 
Lower 
25(OH)D in 
cases 
compared to 
controls  
None 
 
*Cases versus controls 
IGT: Impaired glucose tolerance 
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Table 1-5 Reviewed prospective studies of association between serum 25(OH)D 
concentration and type 2 diabetes mellitus in adults 
 
 
First authorref, 
year , cohort 
[country] 
Age 
(yrs), 
Sex 
Outcome
, Follow-
up (yrs) 
Total 
no./no. 
of cases 
25(OH)D, 
range or 
comparison* 
Main results, 
RR, OR or HR 
(95%CI) 
Adjustments 
Knekt196, 2008, 
Finnish Mobile 
Clinic Health 
Examination 
Survey [Finland] 
40-74, 
M 
 
 
40-74, F 
type 2 
diabetes, 
17 
660/ 223 30 ng/mL vs. 
10 ng/mL  
 
25 ng/mL vs. 
9 ng/mL 
0.49 (0.15,1.64) 
 
 
0.91 (0.37,2.23) 
Age, BMI, exercise, 
season, residence, 
smoking, and 
education 
Knekt196, 2008, 
Mini-Finland 
Health Survey 
[Finland] 
40-69, 
M 
 
 
40-69, F 
type 2 
diabetes, 
22 
714/ 182 30 ng/mL vs. 
10 ng/mL  
 
25 ng/mL vs. 
9 ng/mL 
0.17 (0.05,0.52) 
 
 
1.45 (0.58,3.62) 
Age, BMI, exercise, 
season, residence, 
smoking, and 
education 
Mattila197, 2007, 
Mini-Finland 
Health Survey 
[Finland] 
μ=53, 
M/F 
type 2 
diabetes, 
17 
4097/183 28 ng/mL vs. 
9 ng/mL  
0.67 (0.41-
1.11) 
Age, sex, month, 
BMI, exercise, 
smoking, education, 
blood pressure 
Pittas198, 2010, 
Nurses' Health 
Study [USA] 
μ=56, F type 2 
diabetes, 
15 
1167/ 
608 
33 ng/mL vs. 
14 ng/mL  
0.52 (0.33-
0.83) 
Age, race, fasting 
status, month, 
latitude, smoking, 
physical activity, 
alcohol, multivitamin 
use, trans fat, fiber, 
iron, magnesium, 
fish, calcium intake, 
history of high 
cholesterol, 
hypertension and 
diabetes 
Grimnes199, 
2010, Tromsø 
Study (non-
smokers) 
[Norway] 
μ=60, 
M/F 
type 2 
diabetes, 
11 
4157/ 
183 
14 ng/mL vs. 
29 ng/mL  
1.12 (0.82-
1.54) 
Age, sex, BMI, 
physical activity, 
former smoking 
Grimnes199, 
2010, Tromsø 
μ=57, type 2 
diabetes, 
1962/ 64 20 ng/mL vs. 0.89 (0.78- Age, sex, BMI, 
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Study (smokers) 
[Norway] 
M/F 11 39 ng/mL  1.01) physical activity 
Robinson200, 
2011, Women's 
Health Initiative 
[USA] 
μ=66, F type 2 
diabetes, 
µ=7.3 
5140/317 25 ng/mL vs. 
14 ng/mL 
1.05 (0.62-
1.76) 
Age, ethnicity, 
latitude, month, BMI, 
hypertension, fiber 
intake, magnesium 
intake, and physical 
activity 
Kayaniyil201, 
2011, 
Prospective 
Metabolism and 
Islet Cell 
Evaluation 
Cohort Study 
[Canada] 
μ=50, 
M/F 
Area 
under 
glucose 
curve, 3 
years 
489/116 25 ng/mL vs. 
14 ng/mL 
β=-.001 (-0.002 
to -0.0003) 
p=0.007 
Age, sex, ethnicity, 
season, and 
baseline value of the 
outcome variable, 
physical activity, 
vitamin D 
supplement use, 
and BMI 
Deleskog202, 
2012, Stockholm 
Diabetes 
Prevention 
Program 
[Sweden] 
35-56, 
M/F 
type 2 
diabetes, 
8-10 
years 
808/404 Q4 vs. Q1 0.52 (0.30-
0.90) Men 
Age, sex, ethnicity, 
season, and 
baseline value of the 
outcome variable, 
physical activity, 
vitamin D 
supplement use, 
and BMI 
 
*Highest/lowest risk category versus reference category 
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Figure 1-1 Chapter 1, Overall Flow Diagram of Cohort from NHANES 2001-2006  
 
 
Participants who were interviewed 
(n=31,509)
Participants who were both interviewed and 
MEC examined (n= 30,070)
Participants over the age of 20 (n=14,542) 
Participants with no missing information for 
age, gender, race, 25(OH)D, HbA1c, and CRP 
(n=13,602)
Excluded because 
participant did not fulfill 
inclusion criteria for 
venipuncture (n=940)
Analytic 
Sample 
Participants with no missing information for 
physical activity, smoking status, education, 
physician-diagnosed diabetes and WC 
(n=12,045)
Excluded because of missing 
information for physical 
activity (n=15), smoking 
status (n=16), education 
(n=17), physician-diagnosed 
diabetes (n=218), or 
WC(n=1,557)
 
 
25(OH)D: 25-hydroxyvitamin D, WC: Waist circumference, HbA1c: Hemoglobin A1c 
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2. ASSOCIATION BETWEEN SERUM 25-HYDROXYVITAMIN D 
CONCENTRATION AND INFLAMMATION 
 
 
 
2.1. Abstract 
Background: Support for an association between 25-hydroxyvitamin D 
[25(OH)D] and inflammation is mostly derived from animal and cellular studies. 
Many previously conducted observational studies have had limited 
generalizeability. Therefore, we sought to test the hypothesis that 25(OH)D is 
associated with C-reactive protein (CRP), homocysteine, and fibrinogen using 
data from a nationally representative sample. 
 
Research Design and Methods: We used data from the National Health and 
Nutrition Examination Survey (NHANES) 2001-2006. The analytic sample 
included adults over the age of 20 years with information on 25(OH)D and other 
covariates (n=12,515). Piecewise linear regression was conducted between 
25(OH)D and log-transformed CRP or fibrinogen with a knot introduced at 
25(OH)D=20 ng/mL. In addition, interaction by race/ethnicity, gender, age, and 
abdominal obesity was examined on the association between 25(OH)D and log-
transformed CRP. Linear regression was conducted to determine the association 
between 25(OH)D and log-transformed homocysteine. Logistic regression was 
utilized to examine the association between 25(OH)D and CRP.  
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Results: The association between 25(OH)D and log-transformed CRP was 
negative when 25(OH)D < 20 ng/mL (β=-0.011, 95% CI: -0.012, -0.002) and 
weakly positive when 25(OH)D ≥ 20 ng/mL (β=0.006, 95% CI: 0.002, 0.011) after 
adjustment for confounders. The association was consistent in subgroup 
analyses although there was statistical interaction by race/ethnicity, gender, 
abdominal obesity, and age. In multiple logistic regression analyses, the 
association between 25(OH)D was not associated with CRP. The association 
between 25(OH)D and fibrinogen was not statistically significant. However, there 
was an inverse association between 25(OH)D and log-transformed homocysteine 
(β=-0.003, 95% CI: -0.004, -0.002) after full covariate adjustment.  
 
Discussion: In a nationally representative sample of adults over the age of 20, 
we found some evidence for a protective effect of 25(OH)D on inflammation. 
When 25(OH)D was < 20 ng/mL, 25(OH)D was associated with a lower odds of 
CRP. We also found that 25(OH)D was inversely associated with homocysteine. 
Since this analysis was based on cross-sectional data, these results should be 
confirmed in prospective studies and interventional trials. 
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2.2. Background 
 Recent evidence suggests that vitamin D can inhibit the inflammatory 
response by functioning as an immunomodulator, a substance which can impact 
the immune system.1,2 The vitamin D receptor, which regulates gene expression 
once activated by 1,25(OH)2D3 (active form of vitamin D), is expressed by 
immune cells such as macrophages and monocytes. Macrophage and monocyte 
activation can lead to cytokine generation which can cause inflammation in the 
body. A recently published study reports a new pathway by which vitamin D can 
inhibit cytokine activation and production in monocytes and macrophages.2  In 
this mouse study, monocytes from humans with high serum 25-hydroxyvitamin D 
[25(OH)D] (a biomarker of vitamin D status) concentration resulted in less 
cytokine production than monocytes from humans with low serum 25(OH)D 
concentration through up-regulation of MAPK phosphatase-1. 
 Vitamin D supplementation has been shown to decrease inflammatory 
marker production in cellular studies2-5. However, findings from observational 
studies in humans regarding the association between vitamin D and markers of 
inflammation have been inconsistent.6-12  Furthermore, most of the participants in 
the aforementioned observational  studies were kidney-transplant6,8,10 or type 2 
diabetes11 patients, individuals who are not representative of the general 
population. Recent analysis of a nationally representative sample found that 
vitamin D reduced C-reactive protein [CRP] (biomarker of systemic inflammation) 
when serum 25(OH)D concentration was low, but increased inflammation when 
74 
 
 
serum 25(OH)D concentration was high,13 which is not consistent with 
experimental studies.1,2   
 These unexpected findings motivated us to evaluate if the results were 
consistent within subgroups. Since results from randomized controlled trials 
indicate a reduction in inflammation after vitamin D supplementation among 
elderly patients14-16, we wanted to determine if there was interaction by age. 
Furthermore, since observational studies with obese participants9 and women12 
found an inverse association between 25(OH)D and inflammatory markers, we 
wanted to examine if there was interaction by obesity or gender. Also, given 
racial disparities in 25(OH)D17-19  and serum concentration of CRP20, we also 
wanted to examine if there was interaction by race/ethnicity. Moreover, the 
investigators did not account for seasonal variation or the nonlinear association 
of age with CRP (based on preliminary analysis of the data) in their multivariable 
regression model. 25(OH)D21 and CRP22,23 have both been shown to vary by 
season in healthy adults. Finally, we wanted to examine the association between 
25(OH)D and other inflammatory biomarkers not examined in the previous 
manuscript.13 Therefore, we propose to analyze data from the National Health 
and Nutrition Examination Survey (NHANES) 2001-2006 with the following 
changes: 1) stratification of association between 25(OH)D and CRP by 
race/ethnicity, abdominal obesity, and gender; 2) adjustment for season of 
examination and transformation of age so that there is a stronger linear 
association with CRP; and, 3) examine the association of 25(OH)D with 
homocysteine and fibrinogen, biomarkers of inflammation. 
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2.3. Research Design and Methods 
 NHANES are nationally representative surveys conducted by the National 
Center for Health Statistics (NCHS) (Appendix D), part of the Centers for Disease 
Control and Prevention (CDC). Survey participants come from the U.S. 
noninstitutionalized civilian population, who were obtained using a stratified 
multistage probability sample design (Appendix E). In order to increase the 
reliability and precision of estimates, participant recruitment included 
oversampling of adolescents, elderly persons, non-Hispanic blacks, Mexican 
Americans, and low income non-Hispanic whites.  Survey participants were 
interviewed and invited for a clinical examination. Physical examinations and 
collection of blood samples were conducted in a mobile examination clinic (MEC) 
by trained staff.24 After collection from participants, serum specimens were 
processed, stored, and shipped to the Division of Laboratory Sciences, National 
Center for Environmental Health, Centers for Disease Control and Prevention for 
analysis. 
 Data was analyzed from NHANES 2001-2006 and the analytic sample 
was limited to participants over the age of 20. Survey questions which assess 
smoking status were only asked to participants over the age of 20.25 The 
unweighted response rates for the years 2001–2006 was between 79-84% for 
the interviewed sample and 76-80% for the MEC examined sample.26 
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Serum 25(OH)D Concentration 
 25(OH)D concentration is generally understood to reflect total intake of 
vitamin D from cutaneous synthesis and dietary intake. In NHANES 2001-2006, 
serum 25(OH)D concentration was measured using a radioimmunoassay kit 
(DiaSorin, Stillwater, MN).27 The coefficient of variation for the instrument for the 
years 2001–2006 was between 10–13% and the sensitivity for the assay was 1.5 
ng/mL (Appendix C).28 A report by the Institute of Medicine (IOM) defines 
25(OH)D status as possibly harmful (>50 ng/mL), sufficient (20-50 ng/mL), at risk 
of inadequacy (12-19 ng/mL), or at risk of deficiency (<12 ng/mL). 29 
 
Biomarkers of Inflammation 
 C-reactive protein (CRP) in serum is considered one of the best 
biomarkers of systemic inflammation.30 CRP from serum was measured by latex-
enhanced nephelometry using a Behring Nephelometer at the University of 
Washington, Seattle, WA. The coefficient of variation for survey years 2001-2006 
ranged between 3.1–9.9%.27 Homocysteine in serum was measured by Abbott 
Homocysteine assay on the Abbott AxSym analyzer. The coefficient of variation 
for survey years 2003-2006 ranged between 2.3-3.7%.27 Homocysteine was not 
measured in serum for the NHANES 2001-2002. Fibrinogen in serum was 
measured using the Clauss clotting method among participants 40 years of age 
and older.27 Fibrinogen data was only available in the NHANES 2001-2002. The 
77 
 
 
laboratory procedure manual for fibrinogen from NHANES was not accessible so 
data is not available for coefficient of variation values.   
Covariates 
 Age, race/ethnicity, gender, education, season of examination, physical 
activity, and smoking status were obtained by self-report. Season was assigned 
as winter if the period of examination was between November 1 and April 30 or 
summer if between May 1 and October 31.The average level of physical activity 
was reported on a scale of 1 to 4 (least vigorous to most vigorous). Participants 
were asked whether they had smoked at least 100 cigarettes in their entire life to 
classify their smoking status. Those who answered “yes” were asked whether 
they now smoke cigarettes every day, some days, or not at all. Current smokers 
were those who had smoked at least 100 cigarettes during their lifetime and, at 
the time of the interview, reported smoking either every day or some days. 
Former smokers were those who reported smoking at least 100 cigarettes during 
their lifetime but currently did not smoke. Never smokers were those who 
reported never having smoked 100 cigarettes during their lifetime. Data on high 
density lipoprotein (HDL)-cholesterol were obtained from blood samples. Non-
fasting serum measures of HDL were analyzed using a direct immunoassay 
method. The coefficient of variation for survey years 2001-2006 ranged between 
1.8-2.3% for HDL. 
 Data on anthropometric measurements and blood pressure were obtained 
by health staff during a physical examination.24 Waist circumference (WC) was 
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measured at a point immediately above the iliac crest on the midaxillary line at 
minimal respiration to the nearest 0.1 cm.25 Abdominal obesity was defined as 
WC ≥102 cm for men and WC≥88 cm for women.31 Resting systolic blood 
pressures (SBP) were measured three to four times with a mercury 
sphygmomanometer by trained staff. When more than one blood pressure 
measurement was available, the average SBP measurements were calculated. 
Inclusion Criteria 
 Participants (n=916) over the age of 20 who were interviewed and 
examined in a MEC did not have data for CRP or serum 25(OH)D concentration 
and were removed. After excluding persons with missing data for education (n=8, 
0.06%), WC (n=386, 2.8%), physical activity (n=10, 0.07%), smoking status (n=8, 
0.06%), HDL (n=20, 0.15%), and systolic blood pressure (n=471, 3.46%), the 
sample for analysis comprised N=12,515 individuals. The flow diagram of which 
participants were excluded along with the reason is depicted in Figure 2-1.  
Statistical Analysis 
 SAS 9.2 (SAS Institute, Cary, NC) was used for all calculations and 
analyses. Differences in continuous variables were tested using a t-test and 
differences in categorical variables were assessed using a Pearson’s chi-
squared test.  
 CRP was logarithmically transformed to improve normality. Fit plots using 
the Locally Estimated Scatterplot Smoothing (LOESS) procedure were generated 
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to examine the associations of continuous variables (age, 25(OH)D, HDL, and 
SBP) with log-CRP. LOESS is a nonparametric regression technique which 
allows for smoothing in plots while making few assumptions about the 
relationships between variables. This also allows for visualization of the overall 
shape so that appropriate transformations of variables can be made, if 
necessary. The fit plots for HDL and SBP were linear, but the fit plots for age and 
25(OH)D were not. Therefore, we log transformed age to improve linearity.  
However, we utilized a piecewise approach for the association of 25(OH)D with 
log-transformed CRP (log-CRP) since the association varied under and over 
25(OH)D= 20 ng/mL.   
Piecewise Linear Regression 
 Given the complex, stratified, multistage probability cluster sampling 
structure utilized in the NHANES survey design, piecewise regression was 
conducted using the SAS survey procedures. These include weight, cluster and 
strata statements which allow for the calculation of unbiased population-based 
estimates which reflect the unequal probability of selection, nonresponse 
adjustment, and adjustment to independent population controls. Since data from 
NHANES 2001-2006 was utilized for this analysis, 6-year sample weights were 
used to produce statistically reliable estimates taking into account the complex 
survey design.26  
 Piecewise linear regression allows more than one linear model to fit the 
data at differing ranges of the predictor. A knot is the value of the predictor where 
the slope of the linear function changes. Since the association between 25(OH)D 
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and log-CRP varied under and over 25(OH)D=20 ng/mL, we conducted 
multivariable piecewise linear regression and introduced a knot at 25(OH)D=20 
ng/mL. The model was adjusted for log-age (continuous), gender (male or 
female), race/ethnicity (non-Hispanic White, non-Hispanic Black, Mexican 
American, or other), education level (less than high school, high school diploma, 
or some college education), season of examination (winter or summer), physical 
activity (continuous), smoking status (never smoker, former smoker, or current 
smoker), HDL(continuous) and SBP(continuous). The association was examined 
within subgroups by race/ethnicity, abdominal obesity, and gender. Furthermore, 
multiplicative interaction by race/ethnicity, age, abdominal obesity or gender was 
tested by including a cross-product interaction term in the piecewise regression 
models. 
 
Multiple Logistic Regression 
 In multiple logistic regression analyses, CRP was defined as high-risk (≥ 
0.3 mg/dL) or low-risk (<0.3 mg/dL) to be consistent with clinical guidelines 
proposed by the CDC and American Heart Association.32  Furthermore, in logistic 
regression analyses, we accounted for clustering, stratification, and weighting to 
account for the complex survey design. The association between 25(OH)D status 
as a 4-category variable (possibly harmful, sufficient, at risk of inadequacy, or at 
risk of deficiency) and CRP(high-risk, low-risk) was assessed using multiple 
logistic regression. The association between 25(OH)D status as a binary 
variable, operationalized as sufficient (20-50 ng/mL) or insufficient (<20 ng/mL), 
81 
 
 
and CRP(high-risk, low-risk) was also determined using multiple logistic 
regression. The associations were adjusted for age (continuous), gender (male 
or female), race/ethnicity (non-Hispanic White, non-Hispanic Black, Mexican 
American, or other), education level (less than high school, high school diploma, 
or some college education), season of examination (winter or summer), physical 
activity (continuous), smoking status (never smoker, former smoker, or current 
smoker), HDL(continuous) and SBP(continuous). Multiplicative interaction by 
race/ethnicity, age, abdominal obesity or gender was tested by including a cross-
product interaction term in the separate multiple logistic regression models. 
 
Analyses with other biomarkers of inflammation  
 Data on homocysteine (n=8,554) was available for participants in 
NHANES 2003-2006 and data on fibrinogen was available for participants 40 
years and older in NHANES 2001-2002 (n=2,789). Therefore, 4-year and 2-year 
sample weights were applied for analyses involving homocysteine and 
fibrinogen, respectively. Strata and cluster variables remain the same regardless 
of the years of survey data used for continuous NHANES; therefore, no changes 
were applied to these variables.26 Homocysteine was logarithmically transformed 
to improve normality. To determine the association of 25(OH)D with log-
transformed homocysteine (log-homocysteine) and fibrinogen, multivariable 
linear regression and piecewise regression, were used, respectively. LOESS 
plots indicated a shift in the association between 25(OH)D and fibrinogen when 
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25(OH)D was 20 ng/mL. The association between 25(OH)D and log-
homocysteine was inversely linear in the LOESS plot.  
 Therefore, we conducted a multivariable piecewise regression model to 
determine the association between 25(OH)D and fibrinogen, with a knot 
introduced when 25(OH)D =20 ng/mL. In addition, we conducted multivariable 
linear regression between 25(OH)D and log-homocysteine. Both multivariable 
models included adjustment for log-age (continuous), gender (male or female), 
race/ethnicity (non-Hispanic White, non-Hispanic Black, Mexican American, or 
other), education level (less than high school, high school diploma, or some 
college education), season of examination (winter or summer), physical activity 
(continuous), smoking status (never smoker, former smoker, or current smoker), 
HDL(continuous) and SBP(continuous).  
 
2.4. Results 
 The characteristics of all participants are displayed in Table 2-1 with 
stratification by high-risk (≥ 0.3 mg/dL) versus low-risk (<0.3 mg/dL) indicated by 
CRP. Individuals with high-risk CRP were more likely to be older, female, non-
Hispanic Black of Mexican American, less educated, less physically active, 
abdominally obese, and have been examined in the winter. In addition, 
participants with high-risk CRP were more likely to have higher SBP, lower 
serum 25(OH)D concentration,  and  lower HDL. Smoking status was not 
statistically different between high-risk and low-risk groups but was retained in 
the piecewise and logistic regression models for adjustment.   
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Piecewise Linear Regression 
 The fully adjusted association between 25(OH)D and CRP indicates an 
inverse relationship (β=-0.011, 95% CI: -0.012, -0.002) when 25(OH)D is below 
20 ng/mL (Table 2-2). The association was negative in most subgroups, except 
in the abdominally obese and “Other” racial/ethnic group, although both β-
coefficients were not statistically significant. The significant interaction terms 
indicate heterogeneity in the association by race/ethnicity (p=0.004), gender 
(p=0.05), waist circumference (p<0.0001), and age (p=0.002). 
 The fully adjusted association between 25(OH)D and CRP indicates a 
directly positive relationship (β=0.006, 95% CI: 0.002, 0.011) when 25(OH)D ≥ 20 
ng/mL (Table 2-2). There was statistically significant multiplicative interaction by 
race/ethnicity (p=0.005), gender (p=0.01), waist circumference (p=0.04), and age 
(p=0.03). The association was negative and not significant in the “Other” 
racial/ethnic group but positive in all other subgroups. Although the association 
between 25(OH)D and CRP was positive in most subgroups when 25(OH)D≥ 20 
ng/mL,  the β-estimates were smaller in magnitude than the association when 
25(OH)D<20ng/mL. 
Multiple Logistic Regression 
 When 25(OH)D status was a 4-category variable (possibly harmful, 
sufficient, at risk of inadequacy, or at risk of deficiency), results from multiple 
logistic regression analyses indicate that participants at risk of 25(OH)D 
deficiency had a 44% increased odds of high-risk CRP compared to participants 
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with sufficient 25(OH)D status (OR=1.44, 95% CI: 1.24-1.67) after adjustment for 
age, gender, race/ethnicity, education level, physical activity, season of 
examination, and HDL-cholesterol (Table 2-3). However, after further adjustment 
for smoking status, SBP and abdominal obesity, the association was no longer 
statistically significant (OR=1.16, 95% CI: 0.99-1.36). We found statistically 
significant interaction between 25(OH)D status and race/ethnicity (p<0.0001) or 
abdominal obesity (p<0.0001)but not age (p=0.27) or gender (p=0.11) (results 
not shown in table).  
 When 25(OH)D status was categorized as a binary variable (sufficient or 
insufficient), participants with insufficient 25(OH)D had a 4% increased odds of 
high-risk CRP after full covariate adjustment (OR=1.04, 95% CI: 0.93-1.61) 
(Table 2-3). We found statistically significant interaction between 25(OH)D status 
and CRP on abdominal obesity (p<0.0001)but not race/ethnicity (p=0.67), age 
(p=0.36) or gender (p=0.18) (results not shown in table).  
Analyses with other biomarkers of inflammation 
 The association between 25(OH)D and fibrinogen was negative when 
25(OH)D < 20 ng/mL after complete covariate adjustment (β=-0.88, 95% CI: -
1.99, 0.23) but not statistically significant (Table 2-4). The association between 
25(OH)D and fibrinogen when 25(OH)D ≥ 20 ng/mL was negative in the 
unadjusted model (Table 2-4), however, it became weakly positive and non-
significant after partial and full covariate adjustment. Furthermore, when 
25(OH)D ≥ 20 ng/mL, the association is not statistically significant in any of the 
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models. There was an inverse association between 25(OH)D and log-
homocysteine without adjustment for covariates (β=-0.003, 95% CI: -0.004, -
0.001) (Table 2-5). Furthermore, after covariate adjustment, the association 
remained the same (β=-0.003, 95% CI: -0.004, -0.002). 
 
2.5. Discussion  
 In a nationally representative sample of adults over the age of 20, we 
found some evidence for a protective effect of 25(OH)D on inflammation. We 
determined there was a negative association between 25(OH)D and CRP when 
25(OH)D was < 20/mL and a weak positive association when 25(OH)D was ≥20 
ng/mL. Although there was interaction by race/ethnicity, gender, waist 
circumference, and age, the association within any subgroup was not statistically 
significant when it differed from the overall association. Results from multiple 
logistic regression analyses suggest strong heterogeneity in the association 
between 25(OH)D status and CRP by abdominal obesity status and 
race/ethnicity. There was no evidence of an association between 25(OH)D and 
fibrinogen, however, there was evidence of an inverse association between 
25(OH)D and homocysteine.  
 Experimental evidence indicates that vitamin D plays a role in systematic 
inflammation. First, the presence of vitamin D receptors on inflammatory cells 
suggests that there is a potential role for vitamin D in inflammation.33 Cytokine 
activation and proliferation can cause the destruction of β-cells through 
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apoptosis; vitamin D can inhibit the effects of cytokines by binding with 
inflammatory cells. Second, vitamin D was found to interact with vitamin D 
response elements in the promoter region of cytokine genes to impede 
production.34-36 Third, vitamin D was also found to down-regulate the activation of 
a nuclear factor purported to play a role in insulin resistance.37 Fourth, it has 
been found that changes in serum concentration of calcium [which is strongly 
associated with serum 25(OH)D] can impact cell survival through cytokine down-
regulation.38  Finally, up-regulation of MAPK phosphatase-1 has been shown to 
decrease cytokine production. 2  
 Results from observational studies regarding the association between 
25(OH)D and inflammation have been inconsistent and focused on persons with 
limited generalizeability.6-12 For example, in a cross-sectional study with 147 
obese patients, serum 25(OH)D was inversely associated with inflammation after 
adjustment for BMI, body fat, and body fat percentage.9 However, in a study 
among 109 Chinese patients with type 2 diabetes, vitamin D supplementation 
among those with 25(OH)D was not associated with ferritin and high-sensitivity 
CRP.11  However, it is difficult to generalize the results of these studies because 
there were few participants and most were kidney-transplant or type 2 diabetes 
patients. The present study utilized a large, nationally representative sample of 
participants from across the United States.  
 In the present study, the weakly positive association between 25(OH)D 
and CRP when 25(OH)D ≥ 20 ng/mL was not consistent with animal studies1,2 , 
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but consistent with a recent observational study.13 The association was 
heterogeneous by race/ethnicity, gender, abdominal obesity, and age. There is 
weak evidence that participants classified as “Other” in regards to race/ethnicity 
may have an inverse association when 25(OH)D ≥ 20 ng/mL (β=-0.011, 95% CI: 
-0.033, 0.009). The relationship is unclear because of the small number of 
participants in this racial/ethnic group. The small sample size in the fibrinogen 
analysis precludes conclusions, and our results suggest there is no association 
between 25(OH)D and fibrinogen after full covariate adjustment. Findings from 
the homocysteine analysis were reasonably strong, with full covariate adjustment 
indicating an inverse association between 25(OH)D and homocysteine. The 
constant linear association regardless of 25(OH)D concentration found with 
homocysteine was not true for fibrinogen and CRP. The primary limitation of this 
study is the use of cross-sectional data because the temporal association is 
unclear. Participants with high CRP may change their lifestyle behaviors which 
may improve their 25(OH)D status. This might explain the positive association 
between 25(OH)D and CRP when 25(OH)D ≥ 20 ng/mL.  
 In this current investigation, we found some evidence that serum 25(OH)D 
concentration is protective of risk of inflammation. When 25(OH)D was less than 
the concentration recommended by the IOM (< 20 ng/L), 25(OH)D was 
associated with a lower odds of CRP. We also found that 25(OH)D was inversely 
associated with homocysteine. Since inflammation predicts future risk of 
cardiovascular disease39,40 and diabetes41,42, reducing inflammation through 
higher 25(OH)D may reduce the burden of these diseases.43 If these results are 
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confirmed in prospective studies and randomized controlled trials, improving 
serum concentration of 25(OH)D may help to reduce the unfavorable burden of 
cardiovascular disease and diabetes.  
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2.7 Tables and Figures 
Figure 2-1 Chapter 2, Flow Diagram of Participants and Analytical Sample, 
NHANES 2001-2006 
 
Participants who were both interviewed and MEC 
examined (n= 30,070)
Participants over the age of 20 (n=14,542) 
Participants with no missing information for age, 
gender, season, 25(OH)D, and CRP (n=13,626)
No missing information for education, 
smoking, WC, physical activity, HDL, 
and SBP (n=12,515)
Excluded participants who did 
had missing data for 25(OH)D 
or CRP(n=916)
Excluded because of missing 
information for other 
covariates (n=1,111)
 
25(OH)D: 25-hydroxyvitamin D, WC: Waist circumference, CRP: C-reactive protein, HDL: 
High-density lipoprotein, , SBP: Systolic blood pressure 
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Table 2-1 Characteristics of study sample by serum concentration of C-reactive 
protein, NHANES 2001-2006 
Characteristic Low-risk (≤0.3 
mg/dL) 
 High-risk (>0.3 
mg/dL) 
P-Value* 
Unweighted sample size 7544 4971  
Age (years)  48.3(18.9) 49.7(18.7) <0.0001 
Gender   <0.0001 
 Male 4169(55.3) 1883(37.9)  
 Female 3375(44.7) 3088(62.1)  
Race/Ethnicity   <0.0001 
 Non-Hispanic White 4135(54.8) 2485(50.0)  
 Non-Hispanic Black 1337(17.7) 1065(21.4)  
 Mexican-American 
 
1481(19.6) 1105(22.2)  
 Other 591(7.8) 316(6.4)  
Education    <0.0001 
 Less than high school 2004(26.6) 1517(30.5)  
 High school diploma 1806(23.9) 1217(24.5)  
 Some college 
 
3734(49.5) 2237(45.0)  
Season of examination   <0.0001 
 Winter 3340(44.3) 2441(49.1)  
 Summer 4204(55.7) 2530(50.9)  
Physical activity  2.1±0.8 1.9±0.8 <0.0001 
Systolic blood pressure 
 (mmHg) 
123.9±19.6 126.7±21.3 <0.0001 
Waist Circumference   <0.0001 
 Abdominally obese 3175(42.1) 3671(73.9)  
 Not abdominally 
 obese 
4369(57.9) 1300(26.2)  
Smoking status    0.19 
 Current smoker 3900(51.7) 2509(50.5)  
 Former smoker 1999(26.5) 1311(26.4)  
 Never smoker 1645(21.8) 1151(23.2)  
Serum 25(OH)D (ng/mL) 22.6±9.0 21.3±9.3 <0.0001 
HDL concentration (mg/dL) 54.9±16.2 52.7±16.4 <0.0001 
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Data are presented as means±SD or n(%)  
*P-value represents differences in means±SD or proportions using a two-tailed 
test 
HDL: High-density lipoprotein  
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Table 2-2 Association between serum concentration of 25-hydroxyvitamin D and 
log-transformed C-reactive protein overall and within selected subgroups1, 
NHANES 2001-2006 
Subgroup β-coefficient 95% CI P 
(Interaction)2 
    25-hydroxyvitamin D < 20 ng/mL  
Overall -0.011* -0.012, -0.002 -------------- 
Race/Ethnicity   0.004 
 Non-Hispanic White -0.019* -0.031, -0.009  
 Non-Hispanic Black -0.004 -0.017, 0.009  
 Mexican American -0.008 -0.019, 0.003  
 Other 0.018 -0.003, 0.039  
Gender   0.05 
 Male -0.009 -0.021, 0.002  
 Female -0.010 -0.021, 0.001  
Waist circumference   <0.0001 
 Abdominally obese -0.019* -0.027, -0.011  
 Not abdominally 
 obese 
0.006 -0.006, 0.017  
Age -0.003* -0.005, -0.001 0.002 
     25-hydroxyvitamin D ≥ 20 ng/mL  
Overall 0.006* 0.002, 0.011 -------------- 
Race/Ethnicity   0.005 
 Non-Hispanic White 0.008* 0.003, 0.013  
 Non-Hispanic Black 0.003 -0.028, 0.033  
 Mexican American 0.021* 0.006, 0.037  
 Other -0.011 -0.033, 0.009  
Gender   0.01 
 Male 0.001 -0.007, 0.009  
 Female 0.010* -0.021, 0.001  
Waist circumference   0.04 
 Abdominally obese 0.003 -0.003, 0.010  
 Not abdominally 
 obese 
0.002* 0.002, 0.013  
Age 0.001* 0.0003,0.003 0.03 
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1 Piecewise regression model adjusted for log-age, gender, race/ethnicity, 
education level, physical activity, season of examination, smoking status, systolic 
blood pressure, high-density lipoprotein cholesterol, and abdominal obesity 
2 P-value derived from cross-product interaction term in piecewise regression 
model 
*Indicates that p-value < 0.05 based on two-tailed test  
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Table 2-3 Association between 25(OH)D status and c-reactive protein using a 
weighted logistic regression model, NHANES 2001-2006 
25(OH)D Status Unadjusted OR 
(95 %CI) 
1Partially adjusted 
OR (95 %CI) 
2Fully adjusted* 
OR (95% CI) 
4-category variable    
Risk of deficiency 
(<12 ng/mL)   
1.93 (1.74, 2.14) 1.44 (1.24, 1.67) 1.16 (0.99, 1.36) 
Risk of inadequacy 
(12-19 ng/mL) 
1.30 (1.17, 1.44) 1.13 (1.01, 1.27) 1.00 (0.89, 1.12) 
Sufficient (20-50 
ng/mL)  
1.00 (reference) 1.00 (reference) 1.00 (reference) 
Possibly harmful 
(>50 ng/mL) 
1.11 (0.65, 1.88) 1.20 (0.64, 2.25) 1.57 (0.81, 3.03) 
    
Binary variable    
Insufficient (<20 
ng/mL)   
1.48 (1.36, 1.61) 1.21 (1.08, 1.35) 1.04 (0.93, 1.61) 
Sufficient (20-50 
ng/mL)  
1.00 (reference) 1.00 (reference) 1.00 (reference) 
 
1Adjusted for age, gender, race/ethnicity, education level, physical activity, 
season of examination, and high-density lipoprotein cholesterol 
2Adjusted for age, gender, race/ethnicity, education level, physical activity, 
season of examination, high-density lipoprotein cholesterol, smoking status, 
systolic blood pressure, and abdominal obesity 
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Table 2-4 Association between serum concentration of 25-hydroxyvitamin D and 
fibrinogen, NHANES 2001-2006 
Model 25(OH)D < 20 ng/mL  25(OH)D ≥ 20 ng/mL 
 β-coefficient (95% CI) P*  β-coefficient (95% CI) P* 
Unadjusted -2.04 (-3.51, -0.57) 0.01  -0.21 (-1.00, 0.57) 0.57 
Partial1 -1.32 (-2.40, -0.24) 0.02  0.28 (-0.48, 1.03) 0.45 
Full2 -0.88 (-1.99, 0.23) 0.11  0.42 (-0.39, 1.22) 0.29 
 
*P-value calculation based on two-tailed test  
1Piecewise regression model adjusted for log-age, gender, race/ethnicity, 
education level, physical activity, season of examination, and high-density 
lipoprotein cholesterol 
2Piecewise regression model adjusted for log-age, gender, race/ethnicity, 
education level, physical activity, season of examination, high-density lipoprotein 
cholesterol, smoking status, systolic blood pressure, and abdominal obesity 
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Table 2-5 Association between serum concentration of 25-hydroxyvitamin D and 
log-transformed homocysteine, NHANES 2001-2006 
Model β-coefficient 95% CI P* 
   Unadjusted -0.003 -0.004, -0.001 0.0002 
Partial1 -0.003 -0.004, -0.002 <0.0001 
Full2 -0.003 -0.004, -0.002 <0.0001 
 
*P-value calculation based on two-tailed test 
1Piecewise regression model adjusted for log-age, gender, race/ethnicity, 
education level, physical activity, season of examination, and high-density 
lipoprotein cholesterol 
2Piecewise regression model adjusted for log-age, gender, race/ethnicity, 
education level, physical activity, season of examination, high-density lipoprotein 
cholesterol, smoking status, systolic blood pressure, and abdominal obesity 
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3. ASSOCIATION BETWEEN SERUM 25-HYDROXYVITAMIN D 
CONCENTRATION AND GLUCOSE HOMEOSTASIS: MEDIATION BY 
SYSTEMIC INFLAMMATION 
 
 
3.1 Abstract 
Background: Limited and conflicting reports have examined the potential 
mediating role of inflammation in the relationship between serum 25-
hydroxyvitamin D [25(OH)D] concentration and glucose homeostasis. We tested 
the hypothesis that the association between 25(OH)D concentration and 
hemoglobin A1c (HbA1c) is mediated by C-reactive protein (CRP).  
 
Research Design and Methods: We analyzed 6 years of data from continuous 
NHANES which had unweighted response rates between 76-80% throughout the 
time period. The study sample consisted of adults over the age of 20 from 
NHANES 2001–2006 (n=8,655) with data on serum 25(OH)D concentration, 
CRP, HbA1c, and other potential confounders. The primary outcome measure 
was serum concentration of HbA1c. We specified a path model based on theory 
prior to data analysis and subsequently tested it using path analysis, a 
multivariate regression technique.   
 
Results: Males had lower serum 25(OH)D concentration, higher HbA1c, and 
lower serum CRP than females. The path model fit the data reasonably well for 
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males (RMSEA=0.09, SRMSR=0.05, AGFI=0.91, BCFI=0.90) but not for females 
(RMSEA=0.14, SRMSR=0.07, AGFI=0.83, BCFI=0.86). We estimated that 14.9% 
of the effect of 25(OH)D on HbA1c was mediated through CRP in males.  
 
Discussion: Using nationally representative data, findings from the present 
study provide evidence that the association between 25(OH)D and risk of type 2 
diabetes is mediated by systemic inflammation in males. The mediation effect in 
females is unclear since that path model did not conform well to the data. Since 
we analyzed cross-sectional data, our results should be confirmed in future 
longitudinal studies and randomized control trials.   
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3.2 Background 
 
Systematic review studies indicate that high serum 25-hydroxyvitamin D 
[25(OH)D] concentration (a biomarker of vitamin D status) may be associated 
with lower risk of type 2 diabetes.1-4 Although the mechanism by which 
decreased serum 25(OH)D concentration increases risk of type 2 diabetes 
remains obscure, it has been suggested that vitamin D deficiency may impact 
risk of diabetes through various pathways including impaired pancreatic β-cell 
function, insulin resistance, and systemic inflammation.5,6 Furthermore, the 
presence of vitamin D receptors on inflammatory cells suggests that there is a 
potential role for vitamin D in inflammation.7 Because the activation of 
inflammatory pathways may down-regulate insulin signaling which can cause 
insulin resistance, vitamin D might impact the risk of diabetes through the 
inflammatory response.8-10 However, there have been limited and conflicting 
studies that have examined the role of systemic inflammation in the relationship 
between vitamin D and glucose homeostasis. 11-14  
A recent randomized controlled trial (RCT) found that among 100 diabetes 
patients, vitamin D supplementation led to an increase in 25(OH)D concentration 
and decrease in measured inflammatory biomarkers.12 In a different RCT among 
109 elderly patients with type 2 diabetes, vitamin D supplementation was not 
associated with a significant decrease in ferritin or C-reactive protein (CRP).11 
However, since these patients had type 2 diabetes which is often linked with a 
high degree of inflammation,15,16 it is possible that vitamin D had less of an 
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impact because systemic inflammation was present.17 While suggestive, these 
studies were restricted in that they featured a small sample of treated diabetes 
patients with limited generalizeability. In the present analysis, we aimed to use 
data from the National Health and Nutrition Examination Survey (NHANES), a 
large and nationally representative sample, to explore the mediation effect of 
inflammation on the association between 25(OH)D and hemoglobin A1c [HbA1c] 
(biomarker of glucose homeostasis) using path analysis. 
 
3.2 Research Design and Methods 
 NHANES are conducted by the National Center for Health Statistics 
(NCHS) (Appendix D), part of the Centers for Disease Control and Prevention 
(CDC). Survey participants from the U.S. noninstitutionalized civilian population 
were selected using a stratified multistage probability sample design (Appendix 
E). In order to increase the reliability and precision of estimates, participant 
recruitment included oversampling of adolescents, elderly persons, non-Hispanic 
Blacks, Mexican Americans, and low income non-Hispanic whites.  Survey 
participants were interviewed and invited for a clinical examination. Physical 
examinations and collection of blood samples were conducted in a mobile 
examination clinic (MEC).18 After collection from participants, serum specimens 
were processed, stored, and shipped to the Division of Laboratory Sciences, 
National Center for Environmental Health, Centers for Disease Control and 
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Prevention for analysis. The NCHS ethics review board approved the survey, and 
participants were provided with informed consent prior to participation. 
 In the present study, data were analyzed from NHANES 2001-2006 and 
the analytic sample was limited to participants over the age of 20.19 The 
unweighted response rates for the years 2001–2006 was between 79-84% for 
the interviewed sample and 76-80% for the MEC examined sample.20 
Serum 25(OH)D Concentration 
 In NHANES 2001-2006, serum 25(OH)D concentration was measured 
using a radioimmunoassay kit (DiaSorin, Stillwater, MN).21 25(OH)D 
concentration is generally understood to reflect total intake of vitamin D from 
cutaneous synthesis and dietary intake.22 The coefficient of variation for the 
instrument for the years 2001–2006 was between 10–13% and the sensitivity for 
the assay was 1.5 ng/mL (Appendix C).23 Serum 25(OH)D data files were 
updated in November 2010 and these data were utilized because NCHS has 
recommended that the adjusted data rather than previously available unadjusted 
data be used for all analyses of serum 25(OH)D concentration for NHANES 
2001–2006.24 
HbA1c Concentration 
 HbA1c measurements were obtained using a high performance liquid 
chromatography system. The Boronate Affinity high performance liquid 
chromatography system determines total glycohemoglobin by measuring the 1,2-
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cis-diol group found in hemoglobin A1c. The coefficient of variation was <2% in 
each 2-year cycle. The coefficient of variation for survey years 2001-2006 for 
HbA1c ranged between 1.0-1.5%. 
Covariates 
 Information on age, race/ethnicity, gender, season of examination, 
education level, physical activity, and family history of diabetes were obtained by 
self-report during an interview. Season was assigned as winter if the period of 
examination was between November 1 and April 30 or summer if between May 1 
and October 31. The average level of physical activity was reported on a scale of 
1 to 4 (least vigorous to most vigorous). Participants were defined as having a 
family history of diabetes if they answered “yes” to the following question: 
Including living and deceased, were any of your biological relatives, that is, blood 
relatives, including grandparents, parents, brothers, and sisters, ever told by a 
health professional that they had diabetes?  
 Data on CRP and high density lipoprotein (HDL)-cholesterol were 
obtained from blood samples. CRP was measured by latex-enhanced 
nephelometry using a Behring. Non-fasting serum measures of HDL cholesterol 
were analyzed using a direct immunoassay method. The coefficient of variation 
for survey years 2001-2006 ranged between 3.1–9.9% for CRP and 1.8-2.3% for 
HDL.  
 Data on anthropometric measurements and blood pressure were obtained 
by health staff during a physical examination 18. Waist circumference (WC) was 
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measured at a point immediately above the iliac crest on the midaxillary line at 
minimal respiration to the nearest 0.1 cm.19 Resting systolic and diastolic blood 
pressures were measured three to four times with a mercury 
sphygmomanometer by trained staff. When more than one blood pressure 
measurement was available, the average systolic and diastolic blood pressure 
measurements were calculated. 
Inclusion Criteria 
 Participants (n=1090) who were interviewed and examined in a MEC did 
not have data on age, gender, season, education, serum 25(OH)D concentration, 
CRP and HbA1c so were excluded. Moreover, persons taking diabetes 
medication or insulin were removed from the analysis since treated individuals 
have an unrepresentative HbA1c. Within this subsample, participants with 
missing information for WC, education, physical activity, family history of 
diabetes, HDL, SBP, and DBP were excluded as well (n=1,407).  
 Race/ethnicity is a confounder due to the strong association between skin 
pigmentation and lower 25(OH)D concentration 25,26 as well as associations 
between race/ethnicity and a number of factors (socio-economic status and 
behaviors27) that may increase risk for HbA1c.  Because the path modeling 
approach we chose does not accommodate multi-category variables, during 
preliminary exploratory analyses we collapsed race/ethnicity into two groups and 
examined results for a number of categorizations. Ultimately, we limited the 
sample to non-Hispanic white and non-Hispanic Black participants because that 
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was the categorization that fit the model best and reduced the possibility of 
unmeasured confounding.  The final study sample comprised n=8,655 
individuals.  
Statistical Analysis 
 SAS 9.2 (SAS Institute, Cary, NC) was used to conduct our path analysis 
and all other calculations and analyses. Path analysis is a multivariate regression 
technique that solves set of equations simultaneously in order to estimate 
parameters and test model fit. A path model was tested using a model employing 
maximum likelihood estimation with the Covariance Analysis of Linear Structural 
Equations (CALIS) procedure. Weighting was accounted for which allows for the 
calculation of unbiased population-based estimates reflecting the unequal 
probability of selection, nonresponse adjustment, and adjustment to independent 
population controls. As data from NHANES 2001-2006 was utilized for this 
analysis, 6-year sample weights were used to produce statistically reliable 
estimates.  
 To test hypotheses, the model must be identified. Statistical model 
identification focuses on whether a unique solution for all the model’s parameters 
can be achieved based on the selected theoretical model. Specifically, this 
means that the number of parameters must be less than the number of 
observations, which is the number of variances and covariances among the 
observed variables in the path model.28 Our proposed path model was identified 
since the number of parameters (no. of parameters=35) was less than the 
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number of observations (no. of obs=45). The path model had 10 degrees of 
freedom which is calculated as the difference between the number of parameters 
and observations.  
 Conditions were satisfied for unbiased parameter estimation and 
interpretation of model fit.29 Because no one model fit statistic is accepted as the 
method to confirm that the data conform to a given theoretical model, model fit 
was assessed by several indices: the standardized summary of the average 
covariance residuals (root mean square error of approximation, RMSEA); 
standardized difference between the observed correlation and the predicted 
correlation (standardized root mean square residual, SRMSR); whether the data 
fits better than an independent model (Bentler comparative fit index, BCFI); and 
the proportion of the observed covariance that is explained by model covariance 
that adjusts for model complexity (adjusted goodness of fit index, AGFI). 
Generally accepted values for fit indices are: RMSEA <0.1030, SRMSR <0.08 31, 
BCFI >0.9032, and AGFI>0.90.33 
 Standardized coefficients, which reflect the magnitude of association, and 
95% confidence intervals were reported. The path diagram provides a graphical 
representation of the hypothesized relationships. Hypothesized dependencies 
between the variables were specified prior to analysis. Single-headed arrows 
indicate a direct effect from exogenous to endogenous variable and a double-
headed arrow indicates a correlation among exogenous variables (Figure 3-1). 
The 3 endogenous variables are HbA1c (continuous), 25(OH)D concentration 
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(continuous), and log-CRP (continuous). Values of CRP were log-transformed to 
improve normality. The 6 exogenous variables are race/ethnicity (non-Hispanic 
Black compared to non-Hispanic White), family history of diabetes (yes 
compared to no), age (continuous), WC (continuous), SBP (continuous), and 
HDL (continuous). 
 Season, education, physical activity and diastolic blood pressure were 
dropped from the path model because of non-significance. Gender-stratified 
analyses were conducted since studies have suggested that the association 
between 25(OH)D and diabetes is heterogeneous by gender 34-36. In order to test 
the robustness of our results to the absence of multivariate normality, we 
retested our path model in a sensitivity analysis employing weighted-least 
squares regression.  
 
 3.4 Results 
 Table 3-1 shows the characteristics of participants stratified by gender. 
Males tended to be older, less educated, more physically active, and less likely to 
have a blood relative with diabetes. In addition, males were more likely to have a 
greater WC, lower serum 25(OH)D concentration, higher HbA1c, lower serum 
CRP, lower HDL, higher systolic blood pressure, and higher diastolic blood 
pressure. 
 The path model for the association between 25(OH)D and HbA1c in 
females did not fit the data well, as assessed by RMSEA=0.14, SRMSR=0.07, 
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AGFI=0.83, and BCFI=0.86, all of which were outside the good fit threshold 
levels in Table 3-3. Since the standardized coefficients may not be meaningful if 
the model does not fit the data well, we did not present a path model for females. 
However, we have listed the standardized path coefficients in Table 3-2. The 
direct effect of 25(OH)D on HbA1c was not significant (path coefficient=0.004, 
95% CI: -0.03, 0.03, p=0.28). 
 The proposed path model is presented in Figure 3-1 for males. Several 
model fit statistics were obtained and they suggest that the data fit the model 
reasonably well (Table 3-3). Fit indices including RMSEA=0.09 and 
SRMSR=0.05 suggest a reasonably good fit of the data.  In addition, AGFI and 
BCFI were above the threshold of the recommended 0.90 (AGFI=0.91, 
BCFI=0.90) which indicates that the data fit the model well. All path coefficients 
were statistically significant except for the path between SBP and HbA1c (path 
coefficient=-0.01, 95% CI: -0.04,-0.02). Being non-Hispanic Black had a strong 
direct effect on 25(OH)D (path coefficient=-0.41, 95% CI:-0.44,-0.39). Having a 
family history of diabetes had a direct effect on HbA1c (path coefficient=0.12, 
95% CI: 0.09, 0.15). In addition, as hypothesized, 25(OH)D had a negative direct 
effect on HbA1c (path coefficient=-0.05, 95% CI: -0.08, -0.02). In other words, if 
25(OH)D increases by one standard deviation from its mean, HbA1c would be 
expected to decrease by 0.05 from its mean. The indirect effect of 25(OH)D on 
HbA1c was statistically significant (path coefficient=-0.008, p<0.0001). By 
dividing the indirect effect by the total direct effect, it was calculated that 14.9% of 
the total effect from 25(OH)D to HbA1c was mediated through CRP.   
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 Path model assumptions of multivariate normality were not fulfilled 
because two exogenous variables were binary. Sensitivity to this was tested by 
employing weighted-least squares regression, which is more robust than 
maximum likelihood estimation37; path coefficient results were the same, likely 
due to the large sample size used in this study.38  
 
3.5 Discussion  
 Using data from a large, nationally representative sample of adults over 
the age of 20, the main findings of the present study suggest that the association 
between 25(OH)D and glucose homeostasis is mediated by CRP in males. We 
estimated 14.9% of the effect of 25(OH)D on HbA1c was mediated by systemic 
inflammation since the model is theoretically supported and the fit statistics were 
within good fit threshold levels. However, the study also observes that there was 
no statistically significant association between 25(OH)D and glucose 
homeostasis in females.  
 Our finding in males is consistent with those of the MONICA/Cooperative 
Health Research in the Region of Augsburg (KORA) study, which found that 
inflammation did partially mediate the association between 25(OH)D and incident 
type 2 diabetes.39 In addition, the estimated 16% mediation by CRP on the 
association between 25(OH)D and diabetes was similar to the effect found in the 
present study. Since they adjusted for CRP in addition to interleukin-6, soluble 
intercellular adhesion molecule-1, and interferon-γ-inducible protein-10, it is 
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reasonable that they attributed a higher proportion of the association to mediation 
by inflammation. However, since mediation estimates in their study were not 
gender-stratified, a direct comparison of the results cannot be made. 
 The observed mediation is consistent with physiologic mechanisms. 
Vitamin D may influence the nuclear transcription factors necessary for the 
generation and action of cytokines.40 Furthermore, Vitamin D can make cells less 
sensitive to particular nuclear factors which might cause insulin resistance.41 
Insulin resistance and decreased pancreatic β-cell function are the primary 
pathways by which vitamin D is thought to impact glucose homeostasis.5.The 
present study provides evidence that systemic inflammation is also important to 
think of as a factor on the causal pathway.  
 Previous studies have been limited in their focus on physician-diagnosed 
diabetes patients who likely have better glucose homeostasis than individuals 
unaware of their diabetes status. For example, a study by Cigolini et al. found 
that among elderly patients with type 2 diabetes, higher serum 25(OH)D was 
associated with lower high-sensitivity CRP.14 However, it is difficult to generalize 
the results from their study because of the limited age range and fact that they 
are being treated at a diabetes clinic. The study by Thorand et al. 39 which was 
prospective in nature and found similar results to the present study defined 
incident cases based on self-report. Since cases were confirmed by the treating 
physician or medical chart review, it is likely that patients had better glucose 
homeostasis than undiagnosed cases.  
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 Our attempts to improve fit regarding the path model for females were 
unsuccessful. Polynomial and log transformation of age, 25(OH)D, and HbA1c 
did not improve model fit statistics. Unobserved confounding may explain the 
poor model fit. Nevertheless, the null association between 25(OH)D and HbA1c 
is consistent with several prospective studies in the literature.34-36,42 Studies that 
used data from the Women’s Health Initiative found that neither 25(OH)D34 nor 
supplementation with calcium and vitamin D3 were associated with incident 
diabetes.35 However, most of the women were elderly and ethnically White. 
Another study conducted by the Finnish Mobile Clinic found an association 
between 25(OH)D and type 2 diabetes incidence in men but not in women. 
Lastly, in a recent prospective study, men in the highest quartile of 25(OH)D 
concentration who had prediabetes at baseline had a reduced risk of developing 
diabetes 10 years later; the association was not significant in women.42 Women 
may have decreased sensitivity to the effects of vitamin D in regards to glucose 
homeostasis. This suggests sex hormones may influence the association 
between 25(OH)D and risk of diabetes and is supported by a study where low 
testosterone was associated with greater diabetes risk in men but not in women. 
43 
 While our study enhances generalizeability to undiagnosed diabetes 
patients, a limitation of this study is its cross-sectional nature. Information on 
25(OH)D, CRP, and HbA1c were collected at the same point in time so 
temporality is not assured. However, a recent prospective study provides 
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evidence that inflammation may mediate the association between 25(OH)D and 
HbA1c which supports a chronological association.39  
 By using a large community-based general population sample, we provide 
new evidence that the association between decreased vitamin D and risk of type 
2 diabetes may be mediated by systemic inflammation. Our study estimated that 
about 14.9% of the effect of 25(OH)D on glucose homeostasis is mediated by 
systemic inflammation in males. The result suggests that further studies using a 
prospective cohort or randomized controlled trial design are needed to confirm 
the present findings, as well as to further examine the associations in females. If 
the association between vitamin D and risk of type 2 diabetes, and the mediation 
effect through systemic inflammation are confirmed, it would be of a great public 
health impact regarding the control of the current unfavorable epidemic of 
diabetes through improving vitamin D status, a very cost-efficient approach.  
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3.7 Tables and Figures 
Table 3-1 Characteristics of study sample by gender, NHANES 2001-2006 
Characteristic Male Female P-
Value* 
Unweighted sample size 4181 4474  
Age (years)  51.2(18.6) 49.1(19.2) <0.0001 
Season   0.69 
 Winter 1589(38.0) 1682(37.6)  
 Summer 2592(62.0) 2792(62.4)  
Race/Ethnicity   1.0 
 Non-Hispanic White 3070(73.4) 3285(73.4)  
 Non-Hispanic Black 1111(26.6) 1189(26.6)  
Education    0.02 
 Less than high school 858(20.5) 822(18.4)  
 High school diploma 1100(26.3) 1157(25.9)  
 Some college 
 
2223(53.2) 2495(55.8)  
Physical activity (1: least vigorous, 
4:most vigorous)  
2.2±0.9 2.0±0.7 <0.0001 
Waist circumference (cm) 100.8±14.9 95.3±15.7 <0.0001 
Serum 25(OH)D (ng/mL) 22.6±8.7 23.1±10.4 0.03 
Hemoglobin HbA1c (%) ** 5.4(5.2-5.7) 5.3(5.1-5.6) <0.0001 
Serum C-reactive protein (mg/dL) ** 0.17(0.07-0.38) 0.28(0.11-0.62) <0.0001 
Family history of diabetes   <0.0001 
 Yes 1785(42.7) 2225(49.7)  
 No 2396(57.3) 2249(50.3)  
HDL Cholesterol (mg/dL) 48.9±13.9 60.7±17.0 <0.0001 
Systolic blood pressure (mmHg) 127.0±17.6 124.5±22.4 <0.0001 
Diastolic blood pressure (mmHg) 72.42±12.5 69.2±12.4 <0.0001 
Data are presented as means±SD or median (IQR)** or n(%)  
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*P-value represents differences in means±SD or median (IQR) or proportions 
using t-test or Wilcoxon rank-sum test or Pearson's chi-squared test, 
respectively, using a two-tailed test 
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Figure 3-1 Path analysis diagram among males in study sample, NHANES 2001-
2006 
 
 
 
Log-CRP
25(OH)D HbA1C
SBP
HDL
WC
Age
FHD
Race
-0.05
-0.09 0.09
0.15
0.24
-0.01*
-0.05
0.12
0.11-0.41
-0.18
 
Overall model fit: chi-square (df=10, n=4181) = 377.0, p<0.0001, Root mean 
square error of approximation= 0.09, Standardized root mean square residual 
=0.05, Adjusted goodness of fit=0.91, Bentler comparative fit index = 0.90 
*Path coefficient not statistically significant  
25(OH)D: 25-hydroxyvitamin D, FHD: Family history of diabetes, WC: Waist 
circumference, SBP: Systolic blood pressure, Log-CRP: Log C-reactive protein 
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Table 3-2 Standardized path coefficients and 95% confidence intervals in study 
sample from path model, NHANES 2001-2006 
Path Path 
Coefficient 
95%CI P-Value* 
Males 
Standardized effects on HbA1c    
25(OH)D→HbA1c -0.05 -0.08, -0.02 0.003 
Log-CRP→ HbA1c 0.09 0.06, 0.12 <0.0001 
Age→HbA1c 0.24 0.21, 0.27 <0.0001 
Race→ HbA1c 0.11 0.08, 0.14 <0.0001 
WC→ HbA1c 0.15 0.12, 0.18 <0.0001 
FHD→ HbA1c 0.12 0.09, 0.15 <0.0001 
HDL→ HbA1c -0.05 -0.08, -0.02 0.001 
SBP→ HbA1c -0.01 -0.04, 0.02 0.51 
Standardized effects on Log-CRP    
25(OH)D→Log-CRP -0.09 -0.12, -0.06 <0.0001 
Standardized effects on 25(OH)D    
WC→ 25(OH)D -0.18 -0.21, -0.15 <0.0001 
Race→ 25(OH)D -0.41 -0.44, -0.39 <0.0001 
 
 
 
   
Females 
Standardized effects on HbA1c    
25(OH)D→HbA1c 0.004 -0.03, 0.03 0.28 
Log-CRP→ HbA1c 0.05 0.02, 0.07 0.0004 
Age→HbA1c 0.31 0.28, 0.34 <0.0001 
Race→ HbA1c 0.15 0.12, 0.18 <0.0001 
WC→ HbA1c 0.18 0.15, 0.21 <0.0001 
FHD→ HbA1c 0.10 0.08, 0.12 <0.0001 
HDL→ HbA1c -0.07 -0.10, -0.05 <0.0001 
SBP→ HbA1c 0.05 0.02, 0.09 0.0009 
Standardized effects on Log-CRP    
25(OH)D→Log-CRP -0.13 -0.16, -0.10 <0.0001 
Standardized effects on 25(OH)D    
WC→ 25(OH)D -0.26 -0.28, -0.23 <0.0001 
Race→ 25(OH)D -0.36 -0.38, -0.34 <0.0001 
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25(OH)D: 25-hydroxyvitamin D, FHD: Family history of diabetes, WC: Waist 
circumference, SBP: Systolic blood pressure, Log-CRP: Log C-reactive protein 
*P-value based on two-tailed test 
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Table 3-3 Model fit indices for both path analysis models by gender, NHANES 
2001-2006 
Model fit index Good fit threshold 
  
Model fit statistic 
   Males Females 
Root mean square error approximation 
(RMSEA) <0.10 0.09 0.14 
Standardized root mean square residual 
(SRMSR) <0.08 0.05 0.07 
Adjusted goodness of fit (AGFI) >0.90 0.91 0.83 
Bentler comparative fit index (BCFI) >0.90 0.90 0.86 
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4. ASSOCIATION OF SERUM 25-HYDROXYVITAMIN D 
CONCENTRATION WITH PREDIABETES OR TYPE 2 DIABETES: 
INTERACTION BY RACE/ETHNICITY  
 
 
 
4.1. Abstract 
Background: The association between serum 25-hydroxyvitamin D [25(OH)D]  
concentration and prediabetes has not been well-studied. Moreover, 
heterogeneity by race/ethnicity on the association between 25(OH)D and type 2 
diabetes has not been thoroughly examined. To explore the association between 
25(OH)D and prediabetes or type 2 diabetes, with effect modification by 
race/ethnicity and gender, data was analyzed from the National Health and 
Nutrition Examination Survey (NHANES) 2001-2006. 
 
Research Design and Methods: Participants over 20 years of age without 
missing information for covariates were included in the type 2 diabetes analysis 
(n=12,507). Within this sample, the prediabetes analysis was limited to adults 
without type 2 diabetes (n=10,847). We used multiple logistic regression and 
Poisson regression with robust error variance to assess the association between 
sufficient 25(OH)D status (20-50 ng/mL) and type 2 diabetes or prediabetes. We 
also determined the association within subgroups by race/ethnicity or gender. 
Interaction was assessed through a cross-product interaction term from the 
respective regression model.  
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Results: The association between sufficient 25(OH)D status and type 2 diabetes 
was strong (RR=1.36, 95% CI: 1.19-1.56) but stronger between sufficient 
25(OH)D and type 2 diabetes among those not physician-diagnosed with 
diabetes (RR=1.58, 95% CI: 1.22-2.05). Mexican Americans and non-Hispanic 
Whites had a stronger association between 25(OH)D and diabetes than non-
Hispanic Blacks. There was no association between 25(OH)D sufficiency and 
prediabetes and the association was not significant in gender or racial/ethnic 
subgroups. However, 25(OH)D as a continuous variable was associated with 
prediabetes (OR= 0.99, 95% CI: 0.98-1.00, p=0.02). 
 
Discussion: From a large, nationally representative sample, we were able to 
provide evidence that 25(OH)D sufficiency was associated with type 2 diabetes. 
We also found that the relationship varied by race/ethnicity and was not 
significant in non-Hispanic Blacks. The results from this study do not support that 
25(OH)D has a meaningful impact on prediabetes. Since these data were cross-
sectional, these results should be confirmed in prospective studies and 
intervention trials, with particular focus on the impact of 25(OH)D on risk of 
diabetes in non-Hispanic Blacks.  
 
 
 
 
130 
 
 
4.2. Background 
 The high burden of type 2 diabetes and prediabetes in the United States is 
indicated by the estimated 25.6 million prevalent cases of diabetes and 79 million 
individuals with prediabetes.1 Prediabetes is a condition where the body has poor 
glucose homeostasis putting individuals at a high risk of type 2 diabetes.2 Results 
from the Diabetes Prevention Program suggest individuals with prediabetes can 
modify their lifestyle and significantly reduce risk of type 2 diabetes. 3 However, 
even after aggressive lifestyle changes, there is still risk of diabetes onset.    
 Recent evidence from human studies suggests high serum concentration 
of 25-hydroxyvitamin D [25(OH)D] (biomarker of vitamin D status) may reduce 
the risk of diabetes. 13,26-29  A physiological mechanism by which vitamin D 
influences glucose metabolism remains unclear, however, there is evidence that 
β-cell dysfunction and insulin resistance are part of the pathway.4 Pancreatic β-
cells contain vitamin D receptors and express the 1-α-hydroxylase enzyme which 
catalyzes the conversion of 25(OH)D to the active form of circulating vitamin D 
[1,25(OH)2D].5 Furthermore, 1,25(OH)2D may trigger expression of the insulin 
receptor thereby reducing risk of insulin resistance.6 
 Some human studies support heterogeneity in the association between 
25(OH)D and diabetes by race/ethnicity7 and gender.8,9 Analysis of data from the 
National Health and Nutrition Examination Survey (NHANES) III found that the 
association was not significant in non-Hispanic Blacks but was in non-Hispanic 
Whites and Mexican Americans. In a recent prospective study, men, but not 
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women, with prediabetes with high serum 25(OH)D had a reduced 10-year 
incidence of diabetes.8 However, little research has evaluated effect modification 
by gender or race/ethnicity on the association between 25(OH)D and 
prediabetes.10  Furthermore, there has been limited research regarding the 
association between 25(OH)D and prediabetes. 8,10   
 Results from the NHANES III indicate that within a nationally 
representative sample, participants in the highest quartile of 25(OH)D had a 47% 
reduced odds of prediabetes compared to participants in the lowest quartile of 
25(OH)D after complete covariate adjustment.10 However, the study researchers 
calculated an odds ratio which can overestimate the true relative risk for a 
common outcome such as prediabetes (prevalence of prediabetes in their study 
sample was 31.9%). Furthermore, use of quartiles for 25(OH)D, which is specific 
to their sample, is not directly applicable to other studies because of differences 
in distribution of 25(OH)D in samples.  
 Since the Institute of Medicine (IOM) report on dietary reference intakes 
for calcium and vitamin D recommends 25(OH)D sufficiency between 20-50 
ng/mL, 11 we hypothesized that persons with sufficient 25(OH)D (20-50 ng/mL) 
will have a lower risk of type 2 diabetes and prediabetes compared to individuals 
with insufficient (<20 ng/mL) 25(OH)D. To explore the association between 
25(OH)D status and type 2 diabetes and prediabetes, and also test effect 
modification by race/ethnicity or gender, we propose to examine data from the 
NHANES, a large, nationally representative survey. 
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4.3. Research Design and Methods 
 NHANES are nationally representative surveys conducted by the National 
Center for Health Statistics (NCHS) (Appendix D), part of the Centers for Disease 
Control and Prevention (CDC). Survey participants come from the U.S. 
noninstitutionalized civilian population, who were obtained using a stratified 
multistage probability sample design (Appendix E). In order to increase the 
reliability and precision of estimates, participant recruitment included 
oversampling of adolescents, elderly persons, non-Hispanic blacks, Mexican 
Americans, and low income non-Hispanic whites.  Survey participants were 
interviewed and invited for a clinical examination. Physical examinations and 
collection of blood samples were conducted in a mobile examination clinic (MEC) 
by trained staff.12 After collection from participants, serum specimens were 
processed, stored, and shipped to the Division of Laboratory Sciences, National 
Center for Environmental Health, Centers for Disease Control and Prevention for 
analysis. 
 Data was analyzed from NHANES 2001-2006 and the analytic sample 
was limited to participants over the age of 20. Survey questions which assess 
smoking status were only asked to participants over the age of 20.13 The 
unweighted response rates for the years 2001–2006 was between 79-84% for 
the interviewed sample and 76-80% for the MEC examined sample.14 
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Serum 25(OH)D Concentration 
 25(OH)D concentration is generally understood to reflect total intake of 
vitamin D from cutaneous synthesis and dietary intake.15 In NHANES 2001-2006, 
serum 25(OH)D concentration was measured using a radioimmunoassay kit 
(DiaSorin, Stillwater, MN).16 The coefficient of variation for the instrument for the 
years 2001–2006 was between 10–13% and the sensitivity for the assay was 1.5 
ng/mL (Appendix C).17 
Outcomes 
 Case definition of type 2 diabetes was based on fulfillment of the 
American Diabetes Association criteria18 for diabetes diagnosis [fasting plasma 
glucose (FPG) concentration≥126 mg/dL or two-hour plasma glucose≥200 mg/dL 
during an oral glucose tolerance test (OGTT) or A1c≥6.5% (HbA1c) or an answer 
of “yes” to any of the following questions: (1) “Other than during pregnancy, have 
you ever been told by a doctor or other health professional that you have 
diabetes or sugar diabetes?”; (2) “Are you taking insulin now?”; (3) “Are you 
taking diabetic pills to lower your blood sugar?” 
 Prediabetes was defined as adults without diabetes who fulfilled the ADA 
criteria for prediabetes18 (FPG concentration of 100-125 mg/dL or two-hour 
plasma glucose of 140-199 mg/dL during an OGTT or HbA1c of 5.7-6.4%) or 
answered “yes” to the  following question: “Have you ever been told by a doctor 
or other health professional that you have any of the following: prediabetes, IFG, 
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IGT, borderline diabetes or that your blood sugar is higher than normal but not 
high enough to be called diabetes or sugar diabetes?” 
 A FPG test was performed on eligible participants who were examined in 
the morning session after a 9 hour fast.  Since an OGTT was added to the 
laboratory protocol in NHANES 2005–2006, the 2 hour post-load values (after a 
dose of 75g of glucose) will be included in this analysis. Plasma glucose was 
measured using an enzyme hexokinase method for NHANES 2001-2006 surveys 
and the 2005–2006 values (Hitachi 911) were corrected to the 2003–2004 values 
using the Roche Cobas Mira method. There were changes to the equipment and 
laboratory from NHANES 2003-2004. For NHANES 2005-2006, glucose and 
insulin measurements were performed by the Fairview Medical Center 
Laboratory at the University of Minnesota and for NHANES 2003-2004 glucose 
and insulin measurements were performed by the Diabetes Diagnostic 
Laboratory at the University of Missouri-Columbia. Insulin was measured using 
the Tosoh AIA-PACK IRI immunoenzymometric assay in NHANES 2003-2004 
and the Merocodia Insulin ELISA immunoassay in NHANES 2005-2006. A1C 
measurements were obtained using a high performance liquid chromatography 
system. The Boronate Affinity high performance liquid chromatography system 
determines total glycohemoglobin by measuring the 1,2-cis diol group found in 
hemoglobin A1c. 
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Covariates 
 Age, race/ethnicity, gender, education, season of examination, physical 
activity, and smoking status were obtained by self-report. Season was assigned 
as winter if the period of examination was between November 1 and April 30 or 
summer if between May 1 and October 31.The average level of physical activity 
was reported on a scale of 1 to 4 (least vigorous to most vigorous). Participants 
were asked whether they had smoked at least 100 cigarettes in their entire life to 
classify their smoking status. Those who answered “yes” were asked whether 
they now smoke cigarettes every day, some days, or not at all. Current smokers 
were those who had smoked at least 100 cigarettes during their lifetime and, at 
the time of the interview, reported smoking either every day or some days. 
Former smokers were those who reported smoking at least 100 cigarettes during 
their lifetime but currently did not smoke. Never smokers were those who 
reported never having smoked 100 cigarettes during their lifetime. Data on high 
density lipoprotein (HDL)-cholesterol were obtained from blood samples. Non-
fasting serum measures of HDL were analyzed using a direct immunoassay 
method.  
 Data on anthropometric measurements and blood pressure were obtained 
by health staff during a physical examination 12. Waist circumference (WC) was 
measured at a point immediately above the iliac crest on the midaxillary line at 
minimal respiration to the nearest 0.1 cm. Abdominal obesity was defined as WC 
≥102 cm for men and WC≥88 cm for women.19 Resting systolic blood pressures 
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(SBP) were measured three to four times with a mercury sphygmomanometer by 
trained staff. When more than one blood pressure measurement was available, 
the average SBP measurements were calculated. 
Inclusion Criteria 
 Participants (n=900) over the age of 20 who were interviewed and 
examined in a MEC who did not fulfill the inclusion criteria for venipuncture were 
excluded. After excluding persons with missing data for HbA1c, FPG, or OGTT 
(n=9) or other covariates (n=1,126), the type 2 diabetes analysis comprised 
N=12,507 individuals (Figure 4-1). Furthermore, participants with type 2 diabetes 
(n=1,660) or missing information for other covariates (n=907) were also excluded 
leaving 10,847 adults eligible for the prediabetes analysis. Few (~1%) 
participants are at risk of possible harm due to high serum 25(OH)D 
concentration and were not included, with the exception of our sensitivity analysis 
where 25(OH)D was operationalized in several ways. 
Statistical Analysis 
 SAS 9.2 (SAS Institute, Cary, NC) was used for all calculations and 
analyses. Differences in continuous variables were tested using a t-test and 
differences in categorical variables were assessed using a Pearson’s chi-
squared test. Age was not normally distributed but presented as means±SD 
based on convention.  
 
137 
 
 
Multiple Logistic Regression 
 Given the complex, stratified, multistage probability cluster sampling 
structure utilized in the NHANES survey design, data was analyzed using the 
SAS survey procedures. These include weight, cluster, and strata statements 
which allow for the calculation of unbiased population-based estimates, which 
reflect the unequal probability of selection, non-response adjustment, and 
adjustment to independent population controls. Since data from NHANES 2001-
2006 was utilized for this analysis, 6-year sample weights were used to produce 
statistically reliable estimates taking into account the complex survey design.  
 The association between 25(OH)D status(sufficient or insufficient) and 
type 2 diabetes(yes or no) or prediabetes(yes or no) was assessed with a 
weighted logistic regression model which accounted for clustering and 
stratification. The associations were adjusted for age (continuous), gender (male 
or female), race/ethnicity (non-Hispanic White, non-Hispanic Black, Mexican 
American, or other), education level (less than high school, high school diploma, 
or some college education), season of examination (winter or summer), physical 
activity (continuous), smoking status (never smoker, former smoker, or current 
smoker), HDL(continuous) and SBP(continuous). Furthermore, multiplicative 
interaction between 25(OH)D status and gender or race/ethnicity on diabetes and 
prediabetes was tested by including a cross-product interaction term in separate 
multivariable logistic regression models. The contrast option within the survey 
procedure for logistic regression was utilized to present the odds ratios using a 
joint effects method; we also determined the association within subgroups.  
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 Since the odds ratio may not be a valid estimate of the prevalence ratio 
when the outcome variable has a high prevalence, we used the formula 
recommended by Zhang and Yu20 to correct the odds ratios to derive an estimate 
of association that better represents the prevalence ratio: 
 
In order to apply the above-mentioned formula to our study, P0 indicates the 
prevalence of the outcome in 25(OH)D sufficient group and OR indicates the 
crude odds ratio.  
Poisson Regression 
 Although the correction method presented above is generally accepted as 
a way to correct an odds ratio to yield a prevalence ratio, a direct calculation of 
the prevalence ratio can be performed using a generalized linear model with log 
link and binomial error distribution. However, since our multivariable models 
failed to converge with the log-binomial regression, a modified Poisson approach 
was used with a log link and Poisson error distribution; in addition, robust error 
variances were estimated.21 Survey design effects, including clustering and 
stratification, were accounted for by the Generalized Estimating Equations 
options within the Generalized Linear Modeling (GENMOD) procedure.22 We 
used this approach to calculate a relative risk of the association between 
25(OH)D status and diabetes or prediabetes. Multiplicative interaction between 
25(OH)D status and gender or race/ethnicity on prediabetes was tested by 
including a cross-product interaction term in the Poisson regression models. The 
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estimate option within the GENMOD procedure was utilized to present the 
prevalence ratios using a joint effects method. 
 
Supplementary Analyses 
 To examine the association between 25(OH)D status and type 2 diabetes 
among adults without physician-diagnosed diabetes, we conducted logistic and 
modified Poisson regression with full covariate adjustment. Furthermore, we 
repeated the multivariable adjusted logistic regression analysis with prediabetes 
as the outcome with 25(OH)D used as a continuous variable, quartiles, 4 IOM 
groups (possible harm, sufficiency, risk of inadequacy, risk of deficiency), and 3 
IOM groups (sufficiency, risk of inadequacy, risk of deficiency). We also 
conducted gender- and race/ethnicity-stratified analyses to examine if the 
association was significant within subgroups.  
 
4.4 Results  
 The characteristics of all participants are displayed in Table 4-1 with 
stratification by diabetes and prediabetes status. The proportion of 25(OH)D 
sufficiency was higher for individuals without diabetes or prediabetes. 
Participants with diabetes or prediabetes were more likely to be abdominally 
obese. Adults without diabetes or prediabetes were more likely to be younger, 
female, non-Hispanic White, educated, and physically active compared to 
participants with diabetes or prediabetes. Furthermore, persons with diabetes or 
prediabetes had a higher SBP and lower HDL compared to participants without 
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diabetes or prediabetes. Season of examination did not differ by prediabetes 
status (p=0.47) but was retained in the multiple regression models for 
adjustment.   
Type 2 Diabetes 
 There was evidence of an association between 25(OH)D and type 2 
diabetes in all models presented in Table 4-2. After full covariate adjustment, 
there was a 36% (RR=1.36, 95% CI: 1.19, 1.56) increased risk of type 2 diabetes 
among those with vitamin D insufficiency. The odds ratio overestimated the risk 
of type 2 diabetes compared to the prevalence ratio but correction of the odds 
ratio lead to an estimate close to the calculated relative risk. Furthermore, 
covariate adjustment significantly attenuated the effect of vitamin D insufficiency 
on risk of type 2 diabetes. After including only undiagnosed cases, that is, 
participants who were not physician-diagnosed with diabetes, the association 
between type 2 diabetes and vitamin D insufficiency increased (RR=1.58, 95% 
CI: 1.22-2.05) (Table 4-3).  
 The association between vitamin D sufficiency and diabetes was not the 
same within race/ethnicity categories (results not shown in table): non-Hispanic 
White (OR=1.64, 95% CI: 1.31, 2.05), non-Hispanic Black (OR=1.09, 95% CI: 
0.82, 1.45), Mexican American (OR=1.63, 95% CI: 1.20, 2.22), and Other 
(OR=1.07, 95% CI: 0.69-1.65). Evidence for interaction between race/ethnicity 
and vitamin D insufficiency was moderate in strength (P=0.10) as shown in Table 
4-4. However, the joint effect of vitamin D insufficiency and non-Hispanic Black 
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compared to vitamin D sufficiency and non-Hispanic White decreased the risk of 
type 2 diabetes (p=0.04) less than what would have been expected based on the 
independent impacts of vitamin D insufficiency and non-Hispanic Black.  
Furthermore, compared to Mexican American and vitamin D sufficient 
participants, being non-Hispanic Black and having insufficient 25(OH)D interact 
to antagonistically influence the risk of diabetes (p=0.05)(Table 4-5). These 
results using logistic regression were mostly unchanged using a modified 
Poisson regression model (results not shown); the significance of the interaction 
terms were unchanged but the magnitude of association was slightly attenuated. 
There was no evidence of interaction (p=0.52) by gender on the association 
between 25(OH)D status and type 2 diabetes (Table 4-6). 
Prediabetes 
 Based on the results from Table 4-2, there was no evidence of an 
association between 25(OH)D status and prediabetes after complete covariate 
adjustment (RR=1.05, 95% CI: 0.97-1.13). Furthermore, there was no indication 
of interaction by race/ethnicity (p=0.35 and p=0.30 with non-Hispanic White and 
non-Hispanic Black as the reference, respectively)(Table 4-4 and Table 4-5) or 
gender (p=0.56) (Table 4-6) on the association between 25(OH)D status and 
prediabetes. In our supplementary analyses, prediabetes was not associated 
with 25(OH)D whether categorized in quartiles (p=0.21), 4 IOM groups (p=0.25), 
or 3 IOM groups(p=0.52)(results not shown in table). It was also not significant in 
any of the gender- and race/ethnicity stratified subgroups (results not shown). 
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However, 25(OH)D as a continuous variable was associated with a 1% lower 
odds of diabetes (OR=0.99, 95% CI: 0.98-1.00, p=0.02) )(results not shown in 
table). Furthermore, this result using logistic regression was consistent with the 
modified Poisson regression approach (RR=0.99, 95% CI: 0.99-1.0, p=0.04) 
(results not shown in table).  
4.5. Discussion  
 In a large, nationally representative sample of adults over the age of 20, 
we found evidence that serum 25(OH)D concentration was associated with risk 
of type 2 diabetes. The magnitude of the association was large: for example, 
adults with insufficient 25(OH)D status had a 58% higher risk of undiagnosed 
type 2 diabetes  compared to individuals with sufficient 25(OH)D status. 
Furthermore, we found evidence that the relationship between 25(OH)D status 
and type 2 diabetes varies by race/ethnicity. Specifically, our presented results 
using a joint effects method suggest that non-Hispanic Black and vitamin D 
insufficiency antagonistically interact to influence the risk of diabetes compared 
to non-Hispanic White and vitamin D sufficiency. Lastly, we found no evidence 
that 25(OH)D status has a meaningful influence on risk of prediabetes. There 
was no statistical interaction by gender or race/ethnicity, and the association was 
not significant in gender or racial/ethnic subgroups.  
 Our observation that 25(OH)D is not associated with prediabetes may be 
related to the fact that glucose homeostasis is not poor enough for vitamin D to 
have an impact. Vitamin D stimulates expression of the insulin receptor thereby 
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improving insulin sensitivity6 but there is evidence this only occurs when strong 
insulin resistance is present.23,24 Findings that 25(OH)D was not associated with 
prediabetes in our study are consistent with some results from a recent meta-
analysis.25 However, a recent cross-sectional study has found among healthy 
non-Hispanic White adults, 25(OH)D below the 75th percentile in their sample 
was associated with an increased odds of prediabetes compared to participants 
above the 75th percentile.26 The definition of prediabetes was inconsistent with 
recent ADA guidelines since it was only based on fasting plasma glucose, 
therefore, information from the OGTT and HbA1c test were ignored. In addition, 
covariate adjustment was inadequate since models only included age, gender 
and BMI while other variables associated with 25(OH)D and prediabetes were 
excluded. This report and another cross-sectional study10 also used odds ratios 
to estimate the association between 25(OH)D and prediabetes although 
prediabetes is known to have a high prevalence. Correction of the odds ratio 
using the Zhang and Yu method20 or calculation of a relative risk would have 
attenuated results since the odds ratio overestimates the relative risk for common 
outcomes.  
 Our finding that 25(OH)D status was associated with type 2 diabetes 
whether it was physician-diagnosed or assessed based on glucose control tests 
was expected given the large body of evidence which supports an 
association.11,27-30 In a recent ancillary analysis of the Diabetes Prevention 
Program, participants with a median 25(OH)D concentration of 30.1 ng/mL had a 
28% reduced risk of diabetes compared with adults with a median 25(OH)D 
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concentration of 12.8 ng/mL (HR=0.72, 95% CI: 0.56-0.90) after multivariate 
adjustment. The association was protective in the placebo and intensive lifestyle 
randomized arms.  Participants were followed for a mean of 2.7 years where 
25(OH)D, BMI, and physical activity were measured several times. Therefore, 
these variables were adjusted for in analyses as time-varying covariates. Incident 
diabetes was assessed based on OGTT and FPG testing, with diagnosis 
requiring confirmation by repeat testing.  
 The observation in our study that the association of 25(OH)D was stronger 
with undiagnosed diabetes as opposed to all cases of diabetes is unclear.  The 
physician-diagnosed cases may be taking pharmacologic agents to improve 
glucose control or may have changes in lifestyle behavior that may explain the 
weaker association. It is also possible participants have not been physician-
diagnosed with diabetes because of lack of access to healthcare which may 
reflect socioeconomic status. Undiagnosed cases can be thought of as incident 
cases of diabetes, however, as opposed to prospective studies where time to 
diabetes onset would be known, this information is missing because we analyzed 
cross-sectional data.   
 We also found that the association between 25(OH)D and type 2 diabetes 
was different in non-Hispanic Blacks compared to Mexican Americans and non-
Hispanic Whites. It is possible that non-Hispanic Blacks are less sensitive to 
vitamin D and require higher concentration of serum 25(OH)D to benefit from a 
reduced risk of diabetes. Results from the “Other” racial/ethnic group are difficult 
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to interpret because of the small sample size, however, our analysis suggests 
there is no association between 25(OH)D and type 2 diabetes in this subgroup. 
The absence of an association among non-Hispanic Black individuals was 
consistent with a cross-sectional investigation7 and a recent randomized 
controlled trial which found that vitamin D supplementation among African 
Americans did not improve glycemic control over 3 months.31 Overweight or 
obese African American participants with prediabetes were assigned to the 
placebo or intervention group, where the intervention group received 4000 IU/day 
of vitamin D3. Serum 25(OH)D was approximately 16 ng/mL in both groups at 
baseline and increased to 32 ng/mL after 3 months for the intervention group. 
However, there was no improvement in glycemia for the intervention group at the 
end of the study despite the increase in 25(OH)D. Furthermore, these 
participants were overweight or obese putting them at a further disadvantage in 
terms of glycemic control.32,33  
 The present study has several strengths. First, we had a large sample size 
and enough statistical power to detect a true interaction across subgroups. 
Second, the data comes from a nationally representative sample, however, our 
results may not be representative of the institutionalized population because 
those persons were not sampled. Third, we were able to adjust for known 
confounders on the association between 25(OH)D and diabetes or prediabetes. 
Fourth, measurement of serum 25(OH)D concentration had a low coefficient of 
variation. Fifth, we defined our primary predictor and outcome based on 
recommendations from scientific reports from the IOM and ADA which was not 
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done in previous cross-sectional studies. 8,10,26 The primary weakness of this 
study is based on the analysis of cross-sectional data, where it is unclear if 
serum 25(OH)D reduces the risk of diabetes or if diabetes leads to lower serum 
25(OH)D concentration. However, our study results regarding lower risk of 
diabetes based on higher serum concentration of 25(OH)D is consistent with 
several prospective studies which supports temporality of the association. 8,34-38 
Furthermore, we found an association in undiagnosed cases, which can be 
thought of as incident cases because a physician has not notified them of their 
diabetes status. 
 Previous research has not found effect modification by gender or 
race/ethnicity on the association between 25(OH)D and prediabetes which is 
consistent with our report.10 Prospective studies provide evidence of 
heterogeneity in the association between 25(OH)D and diabetes by gender8,9,39,40 
which our analysis did not show. However, our findings may be related to the 
higher 25(OH)D concentration and lower risk of diabetes in women compared to 
men, rather than any causal mechanism. Lastly, our finding that 25(OH)D 
insufficiency was not associated with higher risk of diabetes among non-Hispanic 
Blacks suggests that the recommended cutpoint by the IOM for 25(OH)D 
sufficiency may not be high enough. Although a biological mechanism has not 
been identified, our results suggest non-Hispanic Blacks may have reduced 
sensitivity to vitamin D and require higher serum 25(OH)D concentration to 
benefit from a lower risk of diabetes. Since our study was cross-sectional, these 
results should be confirmed in prospective studies and intervention trials.  
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4.7 Tables and Figures 
 
 
Figure 4-1 Chapter 4, Flow Diagram of Participants and Analytical Sample, 
NHANES 2001-2006 
 
Participants who were both interviewed and MEC 
examined (n= 30,070)
Participants over the age of 20 (n=14,542) 
Participants with no missing information for age, 
gender, race, season and 25(OH)D (n=13,642)
Excluded because 
participants did not fulfill 
inclusion criteria for 
venipuncture (n=900)
No missing information for 
fasting insulin and HbA1c, 
FPG, or OGTT
(n=11,754)
Excluded because of 
missing information for 
other covariates (n=907)
No missing information for 
HbA1c, FPG, or OGTT 
(n=13,633)
No missing data for physical 
activity, smoking, education, 
WC, HDL and SBP
(n=10,847) 
No missing data for physical 
activity, smoking, education, 
WC, HDL and SBP
(n=12,507)
Excluded because of 
missing information for 
other covariates 
(n=1126)
Prediabetes
Stratum *
Type 2 
Diabetes 
Stratum
*Limited to 
participants without  
type 2 diabetes
Final analytic sample for 
type 2 diabetes outcome
Final analytic sample for 
prediabetes outcome  
HbA1c: Hemoglobin A1c, FPG: Fasting plasma glucose, OGTT: Oral glucose 
tolerance test, WC: Waist circumference, HDL: High-density lipoprotein, SBP: 
Systolic blood pressure 
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Table 4-1 Characteristics of participants ≥ 20 years of age stratified by type 2 diabetes mellitus and 
prediabetes, NHANES 2001-2006 
 
 
Characteristic Diabetes 
Present 
Diabetes 
Absent 
P-value* Prediabetes 
Present 
Prediabetes 
Absent 
P-
value* 
Unweighted sample size 1,660 10,847  3,154 7,693  
Age (years) 61.9±14.3 46.8±18.6 <0.0001 55.4±17.6 43.3±17.9 <0.0001 
Gender (%)   <0.0001   <0.0001 
 Male 876 (52.7) 5170(47.7)  1788 (56.7) 3382 (44.0)  
 Female 784 (47.2) 5678 (52.3)  1367 (43.3) 4311 (56.0)  
Race/ethnicity (%)   <0.0001   0.0002 
 Non-Hispanic White 713 (43.0) 5903 (54.4)  1618 (51.3) 4285 (55.7)  
 Non-Hispanic Black 388 (23.4) 2011 (18.5)  645 (20.4) 1366 (17.8)  
 Mexican-American 433 (26.1) 2153 (19.9)  660 (20.9) 1493 (19.4)  
 Other 126 (7.6) 781 (7.2)  232 (7.4) 549 (7.1)  
Education (%)   <0.0001   <0.0001 
 Less than high 
   
672 (40.5) 2848 (26.3)  1005 (31.9) 1843 (24.0)  
 High school   383 (23.1) 2639 (24.3)  771 (24.4) 1868 (24.3)  
 Some college 
 education 
605 (36.5) 5361 (49.4)  1379 (43.7) 3982 (51.8)  
Waist circumference (%)       
 Abdominally obese 1260 (75.9) 5582 (51.5) <0.0001 1958 (62.1) 3624 (47.1) <0.0001 
 Not abdominally 
 obese 
400 (24.1) 5266 (48.5)  1197 (37.9) 4069 (52.9)  
Physical activity  1.85±0.75 2.11±0.83 <0.0001 2.09±0.81 2.13±0.84 0.03 
Smoking status (%)   <0.0001   <0.0001 
 Current smoker 296 (17.8) 2499 (23.0)  676 (21.4) 1823 (23.7)  
 Former smoker 600 (36.1) 2709 (25.0)  961 (30.5) 1748 (22.7)  
 Never smoker 
 
764 (46.0) 5640 (52.0)  1518 (48.1) 4122 (53.6)  
HDL-Cholesterol (mg/dL) 49.4±14.9 54.8±16.4  51.6±15.0 56.1±16.8  
Systolic blood pressure 
 (mmHg) 
134.7±21.9 123.5±19.7  130.1±20.2 120.9±18.8  
Vitamin D Status (%)   <0.0001   <0.0001 
 Possibly harmful 
 (>50 ng/mL) 
2 (0.1) 74 (0.68)  8 (0.3) 66 (0.9)  
 Sufficiency  
 (20–50 ng/mL) 
 
752 (45.3) 6478 (59.7)  1793 (56.8) 4685 (60.9)  
  At risk of 
 inadequacy  
 (12– 19 ng/mL) 
 
543 (32.7) 2727 (25.1)  873 (27.7) 1854 (24.1)  
 Risk of deficiency 
 (<12 ng/mL) 
363 (21.9) 1569 (14.5)  481 (15.3) 1088 (14.1)  
Season of examination (%)   <0.0001   0.47 
 Winter  852 (51.3)  4927 
 
 1450 (46.0) 3477 (45.2)  
 Summer 808 (48.7) 5921 (54.6)  1705 (54.0) 4216 (54.8)  
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Data are presented as means±SD or n(%)  
*P-value represents differences in means(SD) or proportions using t-test or Pearson's chi-squared 
test using a two-tailed test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
 
 
Table 4-2 Association between 25(OH)D status and type 2 diabetes mellitus or 
prediabetes, NHANES 2001-2006 
25(OH)D Status Age-, gender-, and 
race/ethnicity-
adjusted OR/RR 
(95 %CI) 
Partial -
Multivariable 
OR/RR (95% CI)1 
Full - 
Multivariable 
OR/RR (95% 
CI)2 
   
 Type 2 Diabetes   
Crude odds ratio3    
Insufficient (<20 ng/mL) 1.83 (1.57, 2.12) 1.73 (1.47, 2.03) 1.48 (1.25, 1.74) 
Corrected odds ratio4    
Insufficient (<20 ng/mL) 1.68 (1.48, 1.89) 1.60 (1.40, 1.83) 1.40 (1.22, 1.61) 
Prevalence ratio5    
Insufficient (<20 ng/mL) 1.68 (1.46, 1.92) 1.56 (1.36, 1.80) 1.36 (1.19, 1.56) 
    
 Prediabetes  
Crude odds ratio3    
Insufficient (<20 ng/mL) 1.26 (1.10, 1.43) 1.20 (1.04, 1.38) 1.07 (0.92, 1.23) 
Corrected odds ratio4    
Insufficient (<20 ng/mL) 1.17 (1.07, 1.28) 1.14 (1.03, 1.25) 1.05 (0.94, 1.16) 
Prevalence ratio5    
Insufficient (<20 ng/mL) 1.17 (1.08, 1.26) 1.13 (1.04, 1.23) 1.05 (0.97, 1.13) 
Reference group in all models is sufficient 25(OH)D status [20-50 ng/mL] 
1Adjusted for age, gender, race/ethnicity, season of examination, education level, 
physical activity, smoking status, and systolic blood pressure 
2Adjusted for age, gender, race/ethnicity, season of examination, education level, 
physical activity, smoking status, systolic blood pressure, high-density lipoprotein 
cholesterol, and abdominal obesity 
3 Calculation based on weighted logistic regression model which accounted for 
stratification and clustering 
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4Correction of odds prevalence ratio yielding a prevalence ratio based on the 
formula: 
 
Where P0 indicates the prevalence of the outcome in 25(OH)D sufficient group 
and OR indicates the crude odds ratio 
5Calculation based on Poisson regression model with robust error variance which 
accounted for weighting, stratification, and clustering 
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Table 4-3 Association between 25(OH)D status and undiagnosed type 2 
diabetes mellitus, NHANES 2001-2006 
25(OH)D Status Multivariable OR/RR  
(95% CI)* 
  
Crude odds ratio1  
Insufficient (<20 ng/mL) 1.66 (1.30, 2.12) 
Prevalence ratio2  
Insufficient (<20 ng/mL) 1.58 (1.22, 2.05) 
 
Reference group in both models is sufficient 25(OH)D status [20-50 ng/mL] 
*Adjusted for age, gender, race/ethnicity, season of examination, education level, 
physical activity, smoking status, abdominal obesity, systolic blood pressure, and 
high-density lipoprotein cholesterol 
1 Calculation based on weighted logistic regression model which accounted for 
stratification and clustering 
2Calculation based on Poisson regression model with robust error variance which 
accounted for weighting, stratification, and clustering 
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Table 4-4 Association between 25(OH)D status and type 2 diabetes mellitus or 
prediabetes by race/ethnicity, NHANES 2001-2006 
Race/Ethnicity 25(OH)D Status Multivariable OR 
(95 %CI)* 
P 
(Interaction)** 
      Type 2 Diabetes  
    
Overall   0.10 
Non-Hispanic White Sufficient 1.00 ---- 
Non-Hispanic White Insufficient 1.62 (1.29-2.04) ---- 
Mexican American Sufficient 2.00 (1.53-2.61) ---- 
Non-Hispanic Black  Sufficient 2.48 (1.94-3.15) ---- 
Other  Sufficient 2.91 (1.95-4.34) ---- 
Mexican American Insufficient 3.17 (2.37-4.23) 0.90 
Non-Hispanic Black Insufficient 2.67 (2.14-3.34) 0.04 
Other  Insufficient 3.13 (2.21-4.42) 0.14 
 
 
 
 
 
     Prediabetes  
        
Overall   0.35 
Non-Hispanic White Sufficient 1.00 ---- 
Non-Hispanic White Insufficient 1.12 (0.93-1.34) ---- 
Mexican American Sufficient 1.91 (1.55-2.35) ---- 
Non-Hispanic Black  Sufficient 1.66 (1.32-2.09) ---- 
Other  Sufficient 1.81 (1.36-2.41) ---- 
Mexican American Insufficient 1.76 (1.48-2.09) 0.11 
Non-Hispanic Black Insufficient 1.73 (1.43-2.09) 0.62 
Other  Insufficient 1.69 (1.27-2.25) 0.32 
*Adjusted for age, gender, race/ethnicity, season of examination, education level, 
physical activity, smoking status, abdominal obesity, systolic blood pressure, and 
high-density lipoprotein cholesterol 
**P-value associated with cross-product interaction term between race/ethnicity 
and 25(OH)D status in the weighted logistic regression model 
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Table 4-5 Association between 25(OH)D status and type 2 diabetes mellitus 
among Mexican American and non-Hispanic Black participants, NHANES 2001-
2006 
Race/Ethnicity 25(OH)D Status Multivariable OR 
(95 %CI)* 
P 
(Interaction)** 
      Type 2 Diabetes  
    
Mexican American Sufficient 1.00 ------ 
Mexican American Insufficient 1.59 (1.18-2.15) ------ 
Non-Hispanic Black Sufficient 1.18 (0.87-1.61) ------ 
Non-Hispanic Black Insufficient 1.30 (0.94-1.80) 0.05 
      Prediabetes  
        
Mexican American Sufficient 1.00 ------ 
Mexican American Insufficient 0.90 (0.76-1.06) ------ 
Non-Hispanic Black Sufficient 0.87 (0.65-1.18) ------ 
Non-Hispanic Black Insufficient 0.91 (0.69-1.19) 0.30 
 
*Adjusted for age, gender, race/ethnicity, season of examination, education level, 
physical activity, smoking status, abdominal obesity, systolic blood pressure, and 
high-density lipoprotein cholesterol 
**P-value associated with cross-product interaction term between race/ethnicity 
and 25(OH)D status in the weighted logistic regression model 
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Table 4-6 Association between 25(OH)D status and type 2 diabetes mellitus or 
prediabetes by gender, NHANES 2001-2006 
Gender 25(OH)D Status Multivariable 
OR (95 %CI)* 
P for 
Interaction** 
      Type 2 Diabetes  
    Male Sufficient 1.00 ---- 
Male Insufficient 1.54 (1.22-1.95) ---- 
Female Sufficient 0.77 (0.62-0.95) ---- 
Female Insufficient 1.08 (0.85-1.37) 0.52 
      Prediabetes  
    
Male Sufficient 1.00 ---- 
Male Insufficient 1.05 (0.92-1.20) ---- 
Female Sufficient 0.60 (0.52-0.69) ---- 
Female Insufficient 0.68 (0.57-0.82) 0.56 
 
*Adjusted for age, gender, race/ethnicity, season of examination, education level, 
physical activity, smoking status, abdominal obesity, systolic blood pressure, and 
high-density lipoprotein cholesterol 
**P-value associated with cross-product interaction term between gender and 
25(OH)D status in the weighted logistic regression model 
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5. CONCLUSIONS AND RECOMMENDATIONS 
 
  
 The burden of type 2 diabetes has grown to epidemic proportions worldwide. 
In the United States alone, there are estimated 25.6 million adults with diabetes, 
which is associated with significant medical costs, health complications, and 
mortality. Furthermore, the estimated 79 million individuals with prediabetes in 
the United States suggest diabetes incidence will rise unless novel approaches 
for prevention and management are identified. Established modifiable risk factors 
for diabetes include increased physical activity, improved dietary habits, and 
reduced smoking frequency. Recent evidence suggests that serum concentration 
of 25(OH)D may play a role in diabetes etiology.  
 Serum 25(OH)D concentration is likely the best biomarker of vitamin D 
status.1 Many of the case-control studies in the existing literature on the 
association between 25(OH)D and diabetes are flawed by the measurement of 
25(OH)D status on blood samples collected after diabetes diagnosis. Cross-
sectional studies have generally been consistent in finding that 25(OH)D is 
protective of type 2 diabetes risk but causal inferences are difficult because 
exposure and outcome ascertainment occur simultaneously. Although it is 
possible that individuals’ concentration of 25(OH)D decrease at diabetes onset, 
prospective studies suggest that 25(OH)D predicts incident diabetes because 
diagnosis occurs years after 25(OH)D measurement.  
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 Evidence for mechanisms by which 25(OH)D impacts diabetes risk mostly 
come from experimental studies. The primary pathways by which vitamin D is 
believed to influence risk of diabetes include defects in pancreatic β-cell function, 
insulin sensitivity, and systemic inflammation. Although the effect of inflammation 
on risk of diabetes has been well-studied, few studies have examined the impact 
of vitamin D on systemic inflammation. Furthermore, previous investigations have 
had limited external validity because study samples were restricted to patients 
with type 2 diabetes or hemodialysis. Lastly, few observational studies have 
examined the potential mediating role of inflammation and most have had limited 
generalizeability. 
 In the current investigation, we analyzed data from the continuous NHANES 
from survey years, 2001-2006, for which 25(OH)D measurements were available, 
among adults over the age of 20. We focused on this age group since data on 
smoking was only available for this subgroup and because diagnosed diabetes is 
more likely to be type 2 than type 1 for adults over 20 years of age. Furthermore, 
data on variables hypothesized to be confounders were available for most of the 
sample (Appendix A). NHANES are nationally representative surveys whose goal 
is to monitor health in the United States (Appendix D). Although the survey is 
cross-sectional, results from this survey can enhance generalizeability to the U.S. 
population which many human studies cannot. Furthermore, the large number of 
participants recruited for the survey, particularly when combined across 3 
surveys, provides sufficient power to find small differences. Because previous 
studies have indicated that the impact of 25(OH)D on reducing risk of diabetes is 
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small, analysis of NHANES is appropriate because of the high statistical power 
available in the data set. 
 In the present study, we provide evidence that 25(OH)D is associated with 
CRP and homocysteine, biomarkers of inflammation. However, 25(OH)D was 
inversely associated with CRP only when 25(OH)D < 20  ng/mL. The association 
between 25(OH)D and CRP did not vary in subgroups by race/ethnicity, gender, 
or abdominal obesity; however, there was interaction by age, race/ethnicity, 
gender, and abdominal obesity. Furthermore, these findings included adjustment 
for variables associated with 25(OH)D and inflammation. The finding that 
25(OH)D is associated with inflammation is consistent with observational 
studies2-6, randomized controlled trials7-9, and cellular studies. 10-12 13-15  
 In addition, our regression results using path analysis suggest that 14.9% of 
the association between 25(OH)D and CRP is mediated by CRP. This finding 
was true in males but because the proposed path model did not conform well to 
the data for females, the mediation effect was not clear. Although we used cross-
sectional data, this finding was consistent with analysis of prospective data which 
supports temporality of our observed results.16 Furthermore, our estimate of 
14.9% was consistent with their estimated 16% mediation effect of 25(OH)D on 
inflammation.  
 Heterogeneity on the association between 25(OH)D and risk of diabetes has 
been reported in previous studies by gender and race/ethnicity. Furthermore, 
since few studies have examined the association between 25(OH)D and 
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prediabetes, we evaluated the association and assessed effect modification by 
gender and race/ethnicity. Since a report by the IOM on reference intakes for 
vitamin D and calcium recommends a concentration of 20-50 ng/mL to achieve 
vitamin D sufficiency, we tested the hypothesis that vitamin D sufficiency is 
associated with type 2 diabetes and prediabetes; we also examined interaction 
by gender and race/ethnicity.  
 In this analysis, we were not able to find a significant association of vitamin D 
insufficiency (<20 ng/mL) with prediabetes. The association was not significant in 
gender or racial/ethnic subgroups and there was no statistical interaction. 
However, we found that vitamin D insufficiency was associated with a higher risk 
of diabetes after full covariate adjustment (RR=1.36, 95% CI: 1.19-1.56). Among 
participants who were not physician-diagnosed with diabetes, the association of 
vitamin D insufficiency with risk of diabetes was even stronger (RR=1.58, 95% 
CI: 1.22-2.05). Since these individuals more closely represent incident diabetes 
cases, this association may be more representative of the true relative risk.  
 We found that there was heterogeneity by race/ethnicity on the association 
between vitamin D insufficiency and diabetes risk. Furthermore, using joint 
effects, we found evidence that the association was stronger in non-Hispanic 
Whites and Mexican Americans compared to non-Hispanic Blacks. These results 
suggest that serum 25(OH)D concentration recommendations for sufficiency 
should not be the same for all racial/ethnic groups. Recommendations for higher 
concentration of serum 25(OH)D for non-Hispanic Blacks to be vitamin D 
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sufficient and at lowered risk for diabetes and other cardiometabolic outcomes 
may be warranted. Since non-Hispanic Blacks are already at risk of lower serum 
25(OH)D concentration compared to non-Hispanic Whites, these results, if 
confirmed in prospective studies, pose a significant challenge for this group.  
The results of this undertaking are consistent with biological mechanisms 
and other results from the scientific and medical literature which indicate there is 
an association between 25(OH)D, inflammation, and risk of type 2 diabetes. 
Although we analyzed cross-sectional data, the large sample size and 
generalizeability of the findings provide a distinct advantage over other 
observational studies. Our hypothesis that 25(OH)D is associated with 
prediabetes is not supported from the results of our analysis. Moreover, we did 
not find evidence of statistical interaction by gender on the association between 
25(OH)D and diabetes. However, findings from our analysis do support our other 
hypotheses; specifically, that 25(OH)D is associated with inflammation and type 
2 diabetes, inflammation partially mediates the association between 25(OH)D 
and glucose metabolism, and the association between 25(OH)D and diabetes 
varies by race. We found evidence which indicates there is no association 
between 25(OH)D and diabetes in non-Hispanic Blacks. Therefore, large 
prospective studies and randomized controlled trials should explore the 
association in non-Hispanic Blacks. Furthermore, the recommended serum 
concentration of 25(OH)D by the IOM may not be adequate for non-Hispanic 
Blacks, although our results do support that it may be acceptable for non-
Hispanic Whites and Mexican Americans.  
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In summary, our findings support evidence which suggests systemic 
inflammation is on the pathway between 25(OH)D and risk of diabetes, and is 
consistent with previous work which indicates 25(OH)D is associated with type 2 
diabetes. These results may guide future interventional and prospective studies, 
and if confirmed, increasing serum concentration of 25(OH)D may prove 
instrumental in the prevention and management of type 2 diabetes.  
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APPENDIX A. Selected variables from the NHANES 2001-2002, 2003-2004, 
and 2005-2006 Surveys by Cycle  
 
 
     
Variable [Original coding] 
2001-
02 
2003-
04 
2005-
06 
Eligible age 
group (yrs) 
Demographics     
Age at screening [Continuous]    1+ 
Gender [Male, Female]    1+ 
Race/Ethnicity [Mexican American, Other Hispanic, 
Non-Hispanic White, Non-Hispanic Black, Other 
Race- Including Multi-Racial]    1+ 
Education level [Less than High School, High School 
Diploma, More Than High School]    20+ 
Season of examination (6 month time period when 
examination was performed) [November 1 through 
April 30, May 1 through October 31] 
   
1+ 
Full Sample 2 Year MEC Exam Weight [Continuous]    1+ 
Masked Variance Pseudo-PSU [Continuous]    1+ 
Masked Variance Pseudo-Stratum [Continuous]    1+ 
Inflammatory Markers     
C-reactive protein (mg/dL) [Continuous]    3+ 
Homocysteine (umol/L) [Continuous]    
3+ in 03-04,  
20+ in 05-06 
Fibrinogen (mg/dL) [Continuous]    40+ 
Lipid Profile     
HDL-cholesterol (mg/dL) [Continuous]    
3+ in 01-04, 
6+ in 05-06 
Fasting plasma glucose and glucose tolerance test     
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*Two Hour Glucose (OGTT) (mg/dL) [Continuous]    12+ 
*Fasting Glucose (mg/dL) [Continuous]    12+ 
Other Laboratory Markers     
Glycohemoglobin (%) [Continuous]    12+ 
Serum 25(OH)D (ng/mL) [Continuous]    
6+ in 01-02, 
1+ in 03-06 
Diabetes Questions     
Doctor told you have diabetes [Yes, No]    1+ 
Taking insulin now [Yes, No]    1+ 
Take diabetic pills to lower blood sugar [Yes, No]    1+ 
Ever told have health risk for diabetes [Yes, No]    12+ 
Ever told you have prediabetes [Yes, No]    12+ 
Blood relatives have diabetes [Yes, No]    20+ 
BMI Questions     
Body Mass Index (kg/m**2) [Continuous]     1+ 
Waist Circumference (cm) [Continuous]    1+ 
Physical Activity     
Avg level of physical activity each day [1-4]    16+ 
Smoking     
Smoked at least 100 cigarettes in life [Yes, No]    20+ 
Do you now smoke cigarettes [Yes, No]    20+ 
 
*Represents laboratory values from participants that were randomly assigned to the morning 
session (nationally representative subsample) 
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APPENDIX B.  Revised Analytical Note for NHANES 2000-2006 and 
NHANES III (1988-1994) 25-Hydroxyvitamin D Analysis (Revised November 
2010) 
 
 
Data Advisory:   
  
The purpose of this revised note is to inform users that serum 25-
hydroxyvitamin D (25(OH)D) data from NHANES 2003-2004 and 2005-2006 
have been adjusted for assay drifts, as described below. In addition, this note 
modifies the previous analytical note about two issues that should be addressed 
when analyzing 25(OH)D data from NHANES 2000-2006 and NHANES III (1988-
1994). First, data users should be aware that the 25(OH)D data from the 
NHANES 2003-2006 were most likely affected by drifts in the assay performance 
(method bias and imprecision) over time. These assay drifts are likely due to 
reagent and calibration lot changes in the reformulated DiaSorin assay and  may 
affect comparability, and therefore the interpretability of NHANES data from 
2000-2006. The 2003-2004 and 2005-2006 25(OH)D data are being adjusted to 
account for these assay drifts.  The new 2003-2004 and 2005-2006 adjusted 
25(OH)D data files replaced the unadjusted 25(OH)D files in November 2010. 
NCHS recommends that the adjusted data rather than the previously available 
unadjusted data files be used for all analyses of 25(OH)D.  
 
172 
 
 
Second, users are cautioned about making direct comparisons between 
serum 25(OH)D measurements from NHANES 2000-2006  and measurements 
obtained in NHANES III (1988-1994).  NHANES III  25(OH)D data must be 
adjusted in order to make a valid comparison to the NHANES 2000-2006 survey 
years due to a reformulation of the DiaSorin radioimmunoassay (RIA) kit that 
resulted in a shift in assay results between the two time periods. Therefore, users 
of these various NHANES data sets are cautioned that changes in 25(OH)D 
results over the time period 1988-2006 are affected by the two methodological 
issues described above and both should be considered when evaluating 
whether, and how much, differences over time are due to true changes in the 
vitamin D status of the U.S. population.  
Background 
Measurements of serum 25(OH)D were performed as part of the nutrition 
biomarker component of NHANES III (1988-1994) and in the years 2000-2006 of 
NHANES. These 25(OH)D data are available on public use data files on the 
NCHS/NHANES website for NHANES III and NHANES 2001-2002, 2003-2004 
and 2005-2006. The 25(OH)D data collected in 2000 are available through the 
NCHS Research Data Center (not available in public data sets) because of a 
disclosure risk of confidential information for a single-year data release. 
Additional variables of interest relative to 25(OH)D, such as geography, are only 
accessible through the NCHS Research Data Center (due to increased 
disclosure risk) and are subject to the analytic limitations of data used in that 
setting. Readers should be aware that all issues discussed below in regard to the 
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publicly available data for 2001-2006 also apply to the controlled-access data 
from 2000. 
Measurements of serum 25(OH)D were performed in NHANES III (1988-
1994) and NHANES 2000-2006, at the National Center for Environmental Health, 
CDC, Atlanta, GA using the DiaSorin RIA kit (Stillwater MN). The DiaSorin assay 
kit had been reformulated by the manufacturer in 1998 by introducing an 
antibody that provided improved binding and altering the washing solution to 
reduce non-specific binding.   
Impact of assay reformulation on serum 25(OH)D measurements from NHANES 
III  
Steps were taken to address the changes in assay between NHANES III 
and NHANES 2000-2006.  To assess the magnitude of assay changes that might 
have an impact on any observed trends in serum 25(OH)D in the population, in 
2004 the CDC laboratory reanalyzed a subset of 150 banked serum samples 
from NHANES III using the reformulated version of the RIA assay. The serum 
samples were selected to represent the entire distribution of serum 25(OH)D 
values in NHANES III.  The NHANES III results as measured with the 
reformulated assay were regressed on the NHANES III values obtained with the 
original assay for these 150 specimens.  The average difference between the 
reformulated and original RIA was -12% and is described by the following 
equation: 
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NHANES III 25(OH)D reformulated RIA assay  =  (0.8429* NHANES III 25(OH)D original RIA 
assay) + 2.5762 nmol/L (r = 0.8966).    
 
This adjustment equation was generated after first accounting for the 
assay drift occurring during 2003-2004 with the reformulated DiaSorin assay1. 
The above equation allows an approximation of NHANES III results to the level of 
the reformulated assay used in NHANES 2000-2006. 
    
Impact of assay drift on serum 25(OH)D measurements from the NHANES 2000-
2006  
In addition to the assay reformulation, the CDC laboratory observed drifts 
in the serum 25(OH)D assay performance (as reflected in QC pool shifts in the 
mean, up or down, by up to 10%) over the period of 2003-2006. The variation in 
25(OH)D values appeared to be due to method variation that probably resulted 
from reagent and calibration lot-to-lot variation. Two approaches for adjusting the 
2003-2006 25(OH)D were tried1: 1) a statistical adjustment model based on 
quality control pool data that encompassed the period of method drift, and  
2) a statistical model based on participant 25(OH)D values, transformed by the 
natural logarithm, and an analysis of covariance model to control for time effects 
of assay fluctuations. Both methods gave approximately the same statistical 
adjustment of the 25(OH)D data during 2003-2006. It was decided to use the 
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model based on quality control pool data because the results should be 
independent of any empirical trend in the sample participant data.  
The following weighted descriptive data and selected percentiles 
(calculated using SAS version 9 proc surveymeans) show the effect of the 
adjustment for 2003-2004 and 2005-2006:   
 
Years  Adjusted  N Mean  5th   25th  50th  75th  95th  
2003-2004  No  8294  25.3  9.9  18.3  24.2  30.6  41.4  
2003-2004  Yes  8298*  24.3  9.9  17.9  23.3  29.0  38.9  
2005-2006  No  8306  22.2  8.3  15.9  21.3  27.0  36.0  
2005-2006  Yes  8306  23.9  8.8  17.1  23.1  28.8  38.5  
 
*4 more participants were added for 2003-2004 that were inadvertently missed in 
the unadjusted data. 
 
As seen above, the 2003-2004 25(OH)D data were adjusted to lower 
values and would result in higher prevalence estimates of 25(OH)D deficiency. In 
contrast, the 2005-2006 data were adjusted to higher values and would result in 
lower prevalence estimates of 25(OH)D deficiency. 
 
Future Plans  
 
The National Institute of Standards and Technology (NIST) has released 
standard reference materials for 25(OH)D assays with certified values assigned 
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by use of isotope dilution tandem mass spectrometry (LC-MS/MS) candidate 
reference measurement procedures in July 2009. CDC intends to generate 
regression equations that will permit the adjustment of the 25(OH)D data from 
various NHANES survey years to the NIST accuracy-based standard by 
reanalyzing subsets of specimens from NHANES 1988-1994 and 2001-2006 
using LC-MS/MS. This will improve the ability to interpret the 25(OH)D data for all 
types of analyses, including comparisons between NHANES 2001-2006 and 
NHANES III.  When these equations become available, this analytical note will be 
updated with a revised analytical note.   
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APPENDIX C. Coefficient of Variation Values from Laboratory Procedure 
Manual for Serum 25-Hydroxyvitamin D using Diasorin 25(OH)D Assay: 
NHANES 2001-2002, 2003-2004, and 2005-2006 
 
 
NHANES 2001-2002 
 
NHANES 2003-2004 
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NHANES 2005-2006 
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APPENDIX D. Goals, Survey Methodology, Interviews, Examinations and 
Key Concepts for the Continuous NHANES 
 
 
 
 
Goals of NHANES 
Since its inception, the basic survey goal of monitoring the health status of the 
U.S. population has been refined as well as expanded.  The current goals of the 
NHANES survey are to: 
• Estimate the number and percent of persons in the U.S. population, and 
designated subgroups, with selected diseases and risk factors 
• Monitor trends in the prevalence, awareness, treatment, and control of 
selected diseases 
• Monitor trends in risk behaviors and environmental exposures 
• Analyze risk factors for selected diseases 
• Study the relationship between diet, nutrition, and health 
• Explore emerging public health issues and new technologies 
• Establish a national probability sample of genetic material for future 
genetic research 
• Establish and maintain a national probability sample of baseline 
information on health and nutritional status 
 
 
180 
 
 
Key Concepts About Survey Methodology 
The NHANES program is unique in that it combines interviews with 
physical examinations and laboratory studies. The NHANES program adopted 
several different questionnaire data collection modes to maximize the efficiency, 
quality, and accuracy of questionnaire data.  
 Initial In-person Interview 
In the first step of the continous NHANES survey, all participants complete 
an interviewer-administered questionnaire using Computer-Assisted Personal 
Interview (CAPI) technology.  A large staff of trained interviewers, including 
bilingual interviewers, conduct these interviews in participants' homes.    
The slide below shows a pentop handheld computer, which is currently 
used for the CAPI-administered household interviews. 
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Participants sign consent forms for participating in the interview and 
physical examination.  The physical examination generally occurs within 1 to 2 
weeks after the in-home interview. 
 MEC Examination 
All physical examinations are performed in a set of specially-designed and 
equipped Mobile Examination Centers (MEC), which travel to survey locations 
throughout the country. The survey team currently consists of a physician; 
medical and health technicians; and dietary and health interviewers. 
  
 
To ensure that all physical examination and lab data are collected in 
standardized fashion, and in order to minimize site-specific errors, the MEC and 
examination team provide standardized:  
• environment 
• equipment 
• specimen collection 
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The MEC houses the state-of-the-art exam equipment and is divided into 
rooms to assure the privacy of each study participant during the exams and 
interviews. The full examination for an adult takes approximately 3½  hours, but 
the actual length depends on the study participant's age. The staff at the mobile 
exam center can automatically transmit exam data into databases through such 
devices as digital scales and stadiometers. 
The laboratory component includes the collection and processing of various 
biological and environmental specimens including blood for study participants 1 
year and older, and urine for subjects 6 years and older. On-site pregnancy 
testing excludes pregnant women from other examination components such as 
DEXA, BIA, and cardiovascular fitness testing. Complete Blood Counts (CBCs) 
are also performed in the MEC laboratory. Three medical technologists conduct 
the on-site clinical laboratory tests on biological and environmental specimens, 
record the results of the tests, and prepare and ship specimens to various 
laboratories. All other specimen testing is performed by Federal, private, and 
university-based laboratories under contract to NCHS. 
During the MEC Examination, participants complete additional interviewer-
administered survey questionnaires, including a dietary questionnaire, and 
questionnaires on selected special topics.  CAPI is used to collect these data. 
Selected groups of participants are also asked to complete questionnaires on 
other topics, such as illicit drug  use or sexual behaviors.  Because of the 
sensitive nature of these topics, participants fill out these questionnaires 
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themselves, using Audio Computer-Assisted Self Interview (Audio-CASI) 
technology. 
Key Concepts About Finding Survey Background Information 
The NHANES survey content is determined after a rigorous evaluation 
process including consideration of criteria such as public health importance, 
feasibility of the proposed survey items and burden to survey participants. This 
information is important as you determine the scope of your analysis and which 
variables to include. For example, your analysis may require background 
information, such as: 
• Survey Contents, which shows the years components were collected and 
when changes to the components occurred, 
• Sample Person Questionnaire, and 
• MEC Components Description, which is the survey protocol for obtaining 
the physical examination measures in the survey. 
 
Key Concepts About NHANES Survey Design 
NHANES data are NOT obtained using a simple random sample.  Rather, 
a complex, multistage, probability sampling design is used to select participants 
representative of the civilian, non-institutionalized U.S. population. The sample 
does not include persons residing in nursing homes, members of the armed 
forces, institutionalized persons, or U.S. nationals living abroad. 
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APPENDIX E. Sampling Procedure and Sample Weights for the Continuous 
NHANES 
 
 
NHANES Sampling Procedure 
The NHANES sampling procedure consists of 4 stages, shown and 
described below. 
Four Stages of NHANES Sampling Procedure 
 
• Stage 1: Primary sampling units (PSUs) are selected.  These are mostly 
single counties or, in a few cases, groups of contiguous counties with 
probability proportional to a measure of size (PPS). 
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• Stage 2: The PSUs are divided up into segments (generally city blocks or 
their equivalent). As with each PSU, sample segments are selected with 
PPS. 
• Stage 3: Households within each segment are listed, and a sample is 
randomly drawn. In geographic areas where the proportion of age, ethnic, 
or income groups selected for oversampling is high, the probability of 
selection for those groups is greater than in other areas. 
• Stage 4: Individuals are chosen to participate in NHANES from a list of all 
persons residing in selected households. Individuals are drawn at random 
within designated age-sex-race/ethnicity screening subdomains. On 
average, 1.6 persons are selected per household. 
  
 What is a Sample Weight? 
A sample weight is assigned to each sample person. It is a measure of the 
number of people in the population represented by that sample person in 
NHANES, reflecting the unequal probability of selection, nonresponse 
adjustment, and adjustment to independent population controls. When unequal 
selection probability is applied, as in the NHANES 1999-2002 sample, the 
sample weights are used to produce an unbiased national estimate. More 
information about sample weights and how they are created can be found in the 
Weighting module. 
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Oversampling 
NHANES is designed to sample larger numbers of certain subgroups of 
particular public health interest. Oversampling is done to increase the reliability 
and precision of estimates of health status indicators for these population 
subgroups. 
Examples of oversampled subgroups in the 1999-2004 surveys include: 
• African Americans   
• Mexican Americans 
• Low income  White Americans  (beginning in 2000) 
• Adolescents aged 12-19 years 
• Persons age 60+ years 
 
Different subgroups have been oversampled in other survey years. For 
example, during the late 1960s and early 1970s, there was concern that people 
of very low income and women of childbearing age were at greater risk of 
malnutrition than the general population. Therefore, during the first National 
Health and Nutrition Examination Survey (NHANES I), conducted in 1971-74, 
these subgroups were oversampled. In future surveys, different subgroups may 
be oversampled depending on public health trends. 
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Strata and Masked Variance Units 
The counties in PSUs from two panels of the 1995 National Health 
Interview Survey (NHIS) were used as the sampling frame for NHANES 1999-
2001. The PSU samples for NHANES 2002-2006 and NHANES 2007-2010, were 
selected from a frame of all U.S. counties, using the 2000 census data and 
associated estimates and projections. 
NHANES visited 12 PSUs in 1999 and 15 PSUs in each year from 2000 
through 2006. For NHANES 2007-2010, NHANES will again visit 15 PSUs per 
year. For NHANES 1999-2010, each single year and any combination of 
consecutive years comprise a nationally representative sample of the U.S. 
population. However, in order to obtain stable estimates, two years of data are 
necessary for sufficient sample sizes, hence the data are released in two year 
cycles. 
PSUs are selected from strata defined by geography and proportions of 
minority populations. Most strata contain two PSUs. Together, these strata and 
the PSUs represent the variance units (sampling units used to estimate sampling 
error).   
To protect the confidentiality of data obtained from sample persons, 
masked variance units are constructed. Masked Variance Units (MVUs) are 
equivalent to Pseudo-PSUs used to estimate sampling errors in past NHANES. 
The MVUs on the data file are not the "true" design PSUs. They are a collection 
of secondary sampling units aggregated into groups for the purpose of variance 
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estimation. They produce variance estimates that closely approximate the 
variances that would have been estimated using the "true" design variables. 
These MVUs have been created for each two-year cycle of NHANES and have 
been created in a way that allows them to be used for any combination of data 
cycles without recoding by the user. These MVUs are used to define the strata 
and PSU variables on the public release files. The variable name for the stratum 
is sdmvstra and the variable name for the PSU is sdmvpsu. 
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